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Abstract: Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease 
entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and 
claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this 
review, we aim to give a broad overview of the disease’s nomenclature and epidemiology, as well as the basic mechanisms of emerging 
targeted therapies and their performance in clinical trials to date.
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Overview
Breast cancer classification is in constant   evolution, 
as advances in DNA and RNA microarrays as well 
as  immunohistochemical  (IHC)  staining  allow 
researchers to define the molecular heterogeneity of 
different disease subtypes and to guide the selection of 
appropriate treatment. With routine clinical testing for 
the expression of HER-2/neu in all breast   cancer cases 
and a significantly improved survival rate by trastu-
zumab in women with HER-2/neu positive disease,1–5 
a subtype—triple-negative breast cancer (TNBC)—
has been recognized and garnered recent attention. 
The lack of HER-2/neu coupled with the absence of 
estrogen-receptors (ER) and progesterone-receptors 
(PR)  defines  triple-negative  breast  cancer. Without 
these targets, women with TNBC do not benefit from 
hormonal therapy or trastuzumab, and are left with 
chemotherapy as their only option. TNBC is a disease 
that accounts for approximately 7%–20% of all breast 
cancers6–12 and is known for its aggressive nature and 
poor prognosis. Traditional chemotherapy drugs may 
benefit some of these patients but the relapse rate is 
high and the survival rate continues to lag behind 
other subtypes. The biological specificity of TNBC 
however,  may  be  exploited  in  the    development  of 
novel targeted therapy.
Defining TNBC and basal-like  
breast cancer
One of the difficulties in addressing TNBC is the 
  heterogeneity  of  the  disease  entity.  As  a  result, 
  various terminologies have been used to describe the 
disease and associated biologies. TNBC is a clinical 
term, characterized by the lack of expression of ER, 
PR, and HER-2/neu in a subgroup of breast cancer 
cases. Perou et al defined five molecular subtypes 
(luminal  A  and  B,  HER-2/neu  positive,  normal 
breast-tissue like, and basal-like) in their microarray-
based expression profiling study.13 Basal-like breast 
cancer, which expresses genes usually found in the 
basal cells of the normal breast, has since become 
an  area  of  research  interest.14  While  TNBC  is 
clearly  defined  by  the  absence  of  three  marker 
expressions, there is no universally accepted profile 
of basal-like breast   cancer.15 Nielsen et al compared 
transcriptomic  and  IHC  profiles,  concluding  that 
a panel that was   negative for ER and HER-2/neu, 
and  positive  for  CK  5/6,  and  epidermal  growth 
factor receptor (HER-1 or EGFR) could accurately 
identify  basal-like  carcinomas.16    Korsching  et  al 
included the presence of cytokeratins 14 and 17 in 
the    definition.6  Others  have  proposed  that  some 
  basal-like  tumors  may  be  positive  for  ER  and/or 
HER-2/neu amplification.15,17–22
Though some studies claim basal-like tumors and 
TNBC may be considered synonymous,7,23–25 it has 
been shown repeatedly that though there is significant 
overlap between the two, they are not identical.9,26–28 
When examining basal-like breast cancers, Bertucci 
et al found that 77% were TNBC and 23% were not.26 
Similarly, when Livasy et al and Kandel et al per-
formed IHC testing of a panel of characteristic mark-
ers of basal-like tumors on a group of TNBC tumors, 
they found that only about 85% were basal-like.27,28 
What has become clear is that basal-like carcinoma 
and  TNBC  are  neither  exclusive  nor  synonymous 
diseases.  Both  represent  heterogeneous  types  of 
breast  cancer  and  further  classification  studies  are 
underway.
The  relationship  between  basal-like/TNBC,  and 
BRCA-1-related disease is also of great relevance. 
While probing into the genetic machinery of basal-
like  disease,  it  became  clear  to  researchers  that 
the  tumors  arising  preferentially  in  carriers  of  the 
BRCA-1 mutation, especially those diagnosed before 
the age of 50, bore transcriptomic and IHC profiles 
that were strikingly similar.29–31 BRCA-1 mutations 
lead to derangements in repair pathways of double-
stranded DNA breaks and though a patient may lack 
the BRCA-1 somatic mutation, sporadically arising 
basal-like  cancers  often  display  a  dysfunctional 
BRCA-1 pathway.32,33 Both share certain histological 
features (eg, central necrosis, lymphocytic infiltrate, 
and  genomic  instability34  as  well  as  mutations  in 
p53,22,31,35 which disrupt apoptosis and are associated 
with a poor prognosis.36 As high as 75% of tumors 
in BRCA-1 carriers are reported to be TNBC, basal-
like, or both.15,37 Studies taking a converse approach, 
looking at patients with TNBC but without a significant 
familial  breast  cancer  risk,  found  that  11%–29% 
of that population under 50 are BRCA-1 mutation 
carriers.19,38 It has been suggested recently that for 
women under the age of 50 who are diagnosed with 
TNBC,  BRCA  mutation  testing  is  a  cost-effective 
strategy and should be integrated into genetic testing 
guidelines.39Management options in TNBC
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While  distinct  from  basal-like  cancers,    claudin-
low tumors are triple-negative and are thus considered 
another  subtype  of  triple-negative  disease.  This 
recently discovered claudin-low subtype40,41 takes its 
name from its low expression of the claudin genes. 
It  lacks  epithelial  cell  junction  proteins  including 
E-cadherin, and is marked by intense immune cell 
infiltrate,  stem-cell-like  features,  and  epithelial-
mesenchymal transition features. A study looking at 
tumor-initiating  cells  in  tumor  subtypes  suggested 
that  claudin-low  tumors  are  enriched  with  stem 
cells,  presenting  the  possibility  of  linking  tumor 
initiating cells with stem cells.42 Tumors arresting at 
various points in differentiation would have different 
characteristics  and  it  is  thought  that  claudin-low 
tumors arrest at the step preceding that of basal-like 
phenotypes,  making  it  the  most  primitive  cell  of 
cancer cells.43
At the other end of the spectrum lies the normal 
breast-like group, which can often be mistaken for 
normal breast tissue. Some studies have questioned 
the  existence  of  this  subtype,  though  it  may  be  a 
question of pathological rigor.44 It is a heterogeneous 
subgroup  that  includes  tumors  with  high  stromal 
content, those with high lymphocytic infiltration, and 
those with tumors of low malignant cell content.45 
From breast tumors that resemble primitive stem cells 
to those that closely mimic normal tissue, attempts 
at characterizing TNBC have only reaffirmed a true 
heterogeneity exists within the subtype.
Epidemiology and risk
It has been well-documented that African-American 
women  are  overrepresented  in  the  TNBC 
group.8,10,11,46–48  A  population  based  study  of  the 
California Cancer Registry reported by Bauer et al10 
showed that non-Hispanic black women accounted 
for 10% of all TNBC patients diagnosed and treated 
in  California.  They  were  twice  as  likely  to  be 
diagnosed with TNBC when compared with whites 
and the incidence of black women with TNBC was 
more than twice the incidence of black women with 
other types of breast cancer. Studies by Bauer et al 
and Carey et al8 also showed a worse 5-year survival 
rate for black women with late stage TNBC than for 
other ethnicities.
While most breast cancer cases are associated with 
increasing age, TNBC has a preferential occurrence 
in younger/pre-menopausal women.7,8,10,25,49–51 Phipps 
et al52 and Freedman et al47 found age and menopausal 
status trended to affect recurrence and survival but 
neither reached statistical significance in women with 
TNBC. Demographics, while useful in targeting at-
risk populations, may not be particularly prognostic 
in women already diagnosed with TNBC.
Other  clinical  associations  with  TNBC  patients 
have been ventured as well, such as increased parity, 
young  age  at  first  full-term  pregnancy  (AFFTP), 
elevated waist-to-hip ratio (WHR), gain of adiposity 
since  childhood,  and  obesity.  Though  several 
studies52,53 found that increased parity did not correlate 
with TNBC, Millikan et al48 found that women with 
basal-like  carcinoma  were  more  likely  to  display 
increased parity in combination with a lack of breast-
feeding when compared to women with luminal A 
disease. The data is also split on the significance of 
AFFTP: Millikan et al found an association between 
basal-like disease and younger AFFTP while Phipps 
et al did not.
Women with TNBC, if premenopausal, were also 
more likely to be obese when compared to women 
with other disease subtypes.54–56 Other studies have 
looked  at  more  specific  measurements  like  WHR 
and adiposity gain since childhood. Millikan et al48 
found positive associations between basal-like breast 
cancer and an elevated WHR and a gain of   adiposity 
since childhood. Slattery et al57 similarly found that 
weight gain since age 15 and an elevated WHR were 
both associated with an increased risk of ER-  negative 
breast  cancer.  Metabolic  syndrome  has  also  been 
noted to be more prevalent in TNBC patients than 
those with non-TNBC disease.58 Whether or not any 
of these clinical associations have a causal effect on 
developing TNBC has yet to be elucidated.
Histological tendencies and subtypes
Basal-like carcinomas and TNBC are most likely to be 
infiltrating ductal carcinoma of no special type (IDC-
NST)7,13 but metaplastic, atypical or typical medullary, 
and adenoid cystic cancer, histologies that are usually 
quite rare, are prevalent in TNBCs.24,28,59 Medullary 
cancer in particular has been observed to be a subtype 
that occurs with notable frequency within basal-like 
populations.11,26,60  Both  typical  medullary  cancer 
and basal-like carcinomas have an increased rate of 
p53 mutations35 and share certain genomic alterations Minami et al
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(eg, 1q, 8q and X losses), though other alterations are 
specific to medullary cancer. It may be appropriate to 
consider medullary breast cancers as an entity within 
the basal-like spectrum.60
Large  tumor  size,8,10,26  high  histological  grade 
(75%–100% are grade 3),18,28,61 and poor   differentiation10 
also  mark  basal-like  tumors.  EGFR  overexpression, 
though technically not a basal-like breast carcinoma-
specific  marker,  has  been  found  to  be  present  in 
44%– 50% of samples16,26,62 and, as Nielsen et al sug-
gested, has a strong enough correlation with basal-like 
disease to aid in its identification. It has been shown 
that most tumors that do express c-KIT also express 
basal-like cytokeratins.16 They often have a high Ki-67, 
a marker of poor prognosis even though it is associated 
with a greater chance of chemotherapy response,63 high 
mitotic  index,  and  marked  nuclear  pleomorphism.8 
High  proliferative  rate,  central  necrosis,  a  pushing 
border,  frequent  apoptotic  cells,  scant  stromal  con-
tent, and stromal lymphocytic response are also often 
noted.11,19,28,64 As Rakha et al suggested, histological 
characteristics such as tumor grade, histological sub-
type, and tumor architecture, in combination with other 
features such as patient age and tumor size, may aid in 
the understanding of clinically-identified TNBC.61
Clinical outcomes
As  a  group,  TNBC  and  basal-like  disease  is 
  frequently  thought  of  as  having  poor  outcomes 
(eg,    development  of  distant  metastasis,  shorter 
survival, and higher mortality rate) than other disease 
subtypes.8,10,16,22,31,35,51,65–67 There  are,  however,  data 
suggesting that prognostic outcome should be discussed 
in terms of specific subgroups. For instance, lymph-
node status may be one qualifier, though its significance 
has yet to be clearly defined. Carey et al’s study8 found 
the basal-like subgroup had the poorest breast-cancer 
specific survival amongst all tumor subtypes in both 
lymph node-negative and lymph node-positive patients. 
Van de Rijn et al however, found that in node-negative 
breast cancer, the expression of CK 15 and/or CK 5/6 
was a negative prognostic factor independent of tumor 
size and tumor grade, though they had no predictive 
value in node-positive disease.65 Nielsen et al found the 
presence of basal cytokeratin was associated with poor 
outcome only in the node-positive group.16
The importance of specificity in terms of TNBC vs. 
basal-like discussion was highlighted with Liu et al’s 
study which found that tumors that simultaneously 
over-express  HER-2/neu  and  basal  markers  had  a 
significantly worse 5-year overall survival rate than 
basal-like breast tumors and might require different 
treatment strategy, suggesting that the poor outcomes 
associated with basal-like disease may be a function 
of a variety of factors.68
Subdivisions within the TNBC category by addi-
tional  marker  profiling  exist  as  well.  While  some 
studies  have  shown  that  the  poor  prognosis  of 
TNBC is conferred almost entirely by tumors with 
basal markers,66 Choi et al69 subdivided TNBC into 
  basal-like (ER, PR, HER-2/neu negative, and EGFR 
and CK 5/6 positive) and quintuple-negative breast 
cancer (QNBC) (negative for ER, PR, HER-2-neu, 
CK 5/6, and EGFR). Within the TNBC group, the 
QNBC group had a worse overall survival (OS) than 
the  basal-like  tumors,  emphasizing  that  definition 
and specificity of nomenclature is important when 
  discussing survival data.
The markers that each study uses to define “basal-
like” are also of critical importance. A study by Fulford 
et al used only CK14 staining to identify   basal-like 
tumors among a sample set of grade III IDC-NST 
tumors. The authors found that in the five years fol-
lowing diagnosis, those grade III IDC-NST tumors 
had similar relapse-free survival and OS regardless 
of CK14 expression, but those   expressing CK14 had 
a better prognosis after 5 years. They   suggested that 
two subgroups may exist within basal carcinomas: 
one exhibiting early relapse and aggressive clinical 
course and a separate group that despite the tradi-
tionally poor prognostic indicators do not relapse.64 
Banerjee et al’s study, which also looked at grade III 
carcinomas, screened for CK 5/6, CK 14, and CK 
17, qualifying a case as basal-like if any one of these 
markers  was  found  positive.  Here,  though  women 
with basal-like disease had shorter disease-free sur-
vival (DFS) and OS, basal-like status, as an indepen-
dent prognostic variable, did not reach significance in 
multivariable analysis.70
A  unique  pattern  of  relapse  has  been  observed 
amongst  TNBC:  in  the  first  two  years  following 
  diagnosis, there is a rapid rise in rate of relapse, with 
a peak within three years, followed by a rapid decline 
over the next five, and a very low risk of subsequent 
recurrence.25 The location of relapse also requires some 
discussion. Whether specifically local-regional relapse Management options in TNBC
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(LRR) is higher for basal-like disease than other sub-
types is of some debate, with some studies reporting 
high rates of LRR71 and others failing to find a signifi-
cantly increased risk of isolated LRR after breast-con-
serving surgery.47 The pattern of metastatic relapse has 
been examined in a number of studies, and lung and 
soft-tissue relapse has been found to be more common 
than  bone  relapse  or  lymph-node  metastases.64,71–74 
There is also a greater risk of brain metastases, which, 
along with lung metastases, has been associated with 
a poorer prognosis.64,73,75,76 Because many studies did 
not find a relationship between an increase in tumor 
size and an increase in node-positivity in TNBC dis-
ease  and  because  this  phenomenon  has  also  been 
shown to be present in BRCA-associated cancers, it 
has  been  hypothesized  that  basal-like  disease  may 
have a hematogenous pattern of spread.72,77
Loco-Regional Treatment of Triple-
negative Breast cancer
When triple-negative breast cancer is diagnosed in young 
women, African-American women, women of Jewish 
descent, and women with a high-risk family history of 
breast and/or ovarian cancer, BRCA testing should be 
included as part of the pretreatment assessment. For 
those who test positive for the BRCA1 and BRCA2 
mutation are frequently advised to undergo bilateral 
mastectomy, especially if they are young. Other than 
this subset of patients, the considerations for choosing 
loco-regional treatment for TNBC are the same as for 
other infiltrating ductal cancers. Breast conservation 
surgery  with  postoperative  radiation  remains  to  be 
the choice of local therapy for women with T1 and 
some T2 TNBCs. Mastectomy is reserved for women 
with multicentric disease or with persistently involved 
margins after re-excision. Women with large TNBC 
may still be candidates for breast conservation surgery 
as studies such as ours78 have demonstrated the extreme 
sensitivity of TNBC to neoadjuvant chemotherapy and 
the significant size reduction of the tumor following 
neoadjuvant  treatment.  Mastectomy  in  general 
renders  radiation  unnecessary  unless  the  tumor  is 
5 cm or larger, margins are involved, or there is nodal 
metastasis, but Tseng et al suggested that adjuvant 
radiation in all patients with metaplastic breast cancer 
may lead to improved overall survival.79
Voduc et al80 suggested that basal-like breast   cancer 
and  HER-2  positive  breast  cancer  have  the  worst 
10 year loco-regional survival rate when compared 
with other molecular subtypes of breast cancer after 
breast conservation surgery. This finding raises con-
cerns  about  breast  conserving  surgery  for  women 
with TNBC. However, the same study showed that 
the 10-year loco-regional recurrence rate after mas-
tectomy was also the highest among basal-like TNBC 
and HER-2 positive breast cancer. Therefore, the poor 
relapse-free survival rate observed in these women is 
more likely to be the result of the biology of TNBC and 
less likely to be dictated by the type of surgery. In our 
own analysis of TNBC treatment at UCLA, we found 
that treatment factors such as lumpectomy, radiation, 
and negative surgical margins were associated with 
significantly  better  relapse-free  survival  in  women 
with TNBC. Though LRR rate may be higher7,81 and 
time to recurrence may be shorter in TNBC patients,25 
we believe that lumpectomy followed by postopera-
tive adjuvant radiation is an excellent local treatment 
for many with this disease subtype,82 and we put a 
strong emphasis on clean surgical margins regardless 
of the type of surgery chosen.
Mechanisms of Therapeutic Agents  
in TnBc Treatment
Chemotherapy
Though new targeted biologic therapies show prom-
ise  in  many  other  subtypes  of  breast  cancer,  che-
motherapy remains the only therapeutic option for 
patients  with  TNBC.  TNBC’s  superior  sensitivity 
and responsiveness to chemotherapy has been well 
documented and while doxorubicin and taxanes are 
the classic choices, the most efficacious chemothera-
peutic regimen has not yet been clearly established. 
Recent interest has focused on several classes of che-
motherapeutic agents whose mechanisms of action 
target the unique molecular defects of TNBC.
platinum salts
It is well established that TNBC is prevalent among 
carriers  of  BRCA1  and  BRCA2  mutations.83–85 The 
cancers of these women frequently have a defect in 
homologous recombinant DNA repair, which prevents 
the repair of double-stranded DNA breaks. A similar 
derangement has also been seen in sporadic TNBC. It 
is thought that DNA damaging agents, such as the plat-
inum salts, which bind directly to and cross-link DNA, 
are likely to lead to an irreversible collapse of DNA Minami et al
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repair and achieve the desirable therapeutic result.86 
The expression of p63/p73 proteins expressed in about 
33% of TNBC patients, might be a potential biomarker 
indicating platinum sensitivity of the tumor.87
Anti-tubulin agents
Antitubulin  agents  can  be  divided  into  taxanes 
  (paclitaxel  and  docetaxel)  and  non-taxane  (vinca 
alkaloids,  ixabepilone,  eribulin)  drugs.  Both  work 
through the stabilization of microtubules; by acting 
on the spindle, they block the metaphase-anaphase 
transition and ultimately lead to cell-cycle arrest and 
apoptosis.
Ixabepilone, a semi-synthetic antineoplastic agent 
derived from the natural epithilones,88 was designed 
to have a low susceptibility to mechanisms causing 
drug resistance,89 holding a theoretical advantage over 
taxanes by bypassing drug efflux pumps and binding 
to beta-tubulin in a different manner than taxanes.89–93 
Ixabepilone-sensitivity  may  be  correlated  with  the 
tumor expression of high beta-III tubulin (a type of 
tubulin highly expressed in TNBC, basal-like, and 
HER2+ tumors, and a marker of taxane-resistance)93 
and inversely related to ER expression levels.89 Both 
ixabepilone and eribulin, new non-taxane microtubule 
dynamics inhibitors, may also have an important role 
in the treatment of metastatic disease, especially in 
patients with anthracycline/taxane-resistant   metastatic 
disease.94,95
Targeted Therapy
poly-adenosine-diphosphate ribose-
polymerase (pARp) inhibitors
Agents of this class are a promising targeted therapeu-
tic for TNBC. PARP is an enzyme recruited by either 
single-stranded or double-stranded DNA breaks (SSB 
or  DSB)  for  base-excisional  repair.  Its  zinc  finger 
domain binds to the SSB and cleaves off NAD+, which 
in turn causes the attachment of multiple ADP-ribose 
units and unwinding of the damaged DNA for repair. 
Because of the depletion of NAD+, tumor necrosis is 
frequently seen in tumors with PARP overaction such 
as  TNBC/basal-like  breast  cancers.  The  overactive 
PARP can also increase the release of apoptosis-induc-
ing factor from mitochondria and cause cell death and 
necrosis.96 Most PARP inhibitors mimic NAD+, thus 
blocking the binding of NAD+ to the PARP enzyme 
and inhibiting base-excision repair.
In tumor cells with BRCA1 and BRCA2 deficiencies, 
the  repair  of  DSB  is  impaired  through  deranged 
homologous recombination repair pathways. Further 
blockage by PARP1 inhibitors induce SSBs, stalled 
replication forks, and persistent DSBs ultimately lead 
to cell-cycle arrest and apoptosis.97 Augmented cell 
death caused by the repair block of both SSB and 
DSB is known as synthetic lethality.
Beyond its role in base-excision repair of DNA 
damage, PARP has also been implicated in other vital 
functions for cancer growth, such as tumor angio-
genesis  through  the  modulation  of  tumor-released 
  hypoxia-inducible  factor  and  vascular  endothelial 
growth factor.98,99
Given the BRCA1 pathway dysfunction also seen in 
sporadic TNBC, PARP inhibitors should theoretically 
be effective not only in the tumors of carriers with 
BRCA mutations but also in sporadic TNBC as well. 
Currently, clinical studies are investigating the efficacy 
of PARP inhibitors in both patient populations while 
bench research is delving into the mechanisms of tumor 
growth suppression and predictive markers of response 
to PARP-inhibitor treatment.
Anti-angiogenic agents
Anti-vEGF
Shown to be elevated in TNBC, vascular endothelial 
growth factor (VEGF), a key mediator of angiogenesis, 
may  play  an  important  role  in  the  progression  of 
TNBC given this disease subtype’s penchant for high 
proliferation.100  VEGF  stimulated  the  proliferation 
and migration of epithelial cells, inhibits apoptosis of 
endothelial tissue, increases vascular permeability and 
vasodilation. Bevacizumab (Avastin), the best known 
anti-angiogenic  agent,  is  a  humanized  monoclonal 
antibody (mAb) that binds to VEGF and prevents it 
from  interacting  with  vascular  endothelial  cells.101,102 
Bevacizumab  was  shown  to  have  added  value  when 
combined with chemotherapy in patients with hormone 
receptor (HR) negative breast cancer, although as a group 
the benefits and toxicities of anti-angiogenesis drugs in 
breast cancer treatment has not been clearly established.
Anti-EGFR
Although EGFR/HER1 is not a specific marker for 
basal-like breast cancer, its over-expression has been 
found in 44%–78%16,62 of these tumors and may be an 
important prognostic marker in long-term survival.51 Management options in TNBC
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Similarly, over-expression of EGFR is also found in 
TNBC23,26,103 and there may be an inverse relation-
ship between estrogen receptor expression and EGFR 
amplification.62 TNBC cell growth and survival may 
be supported by   signaling via EGFR over-expression 
and increased ligand levels.
Expression of TIMP-2, an endogenous inhibitor for 
several ADAM (a disintegrin and metalloproteinase) 
and matrix metalloproteinase (MMP) family members, 
inhibits Erb-B ligand and receptor shedding by the 
tumor and tumor suppression in vivo. In many human 
tumors, reduced TIMP-3 expression correlated with 
disease suppression.104 These results suggest ADAM 
inhibitors INCB7839 (an inhibitor of ADAM 10 and 
ADAM 17) and TMI-002, an inhibitor specific for 
ADAM 17, may suppress the downstream signaling 
from all EGFR family members. Drugs have been 
developed to target both the extra-cellular domain of 
EGFR (monoclonal antibodies) and the intracellular 
domain  (tyrosine  kinase  inhibitors).  Clinical  trials 
evaluating cetuximab, a humanized anti-EGFR IgG1 
antibody, panitunumab, a full human anti-EGFR anti-
body,  gefitinib  and  erlotinib,  both  small  molecule 
tyrosine kinase inhibitors in TNBC are encouraging.
Multi-tyrosine kinase inhibitors
C-src, the cellular homolog of the viral oncogene v-src, 
is a non-receptor signaling kinase that works down-
stream of multiple growth factors including platelet-
derived  growth  factor  receptor  (PDGFR),  EGFR, 
IGF−1. It plays an important role in cancer cell prolif-
eration and invasion through multiple pathways.
Dasatinib  is  an  orally  active  small  molecule 
inhibitor of both scr and abl proteins. In vitro studies 
show  that  dasatinib  inhibits  growth  of  “basal-like/
triple-negative” breast cancer cell lines both as a single-
agent, and also in combination with chemotherapy 
(namely 5’-5’-DFU or cisplatin).105
Other targeted therapies
mTOR inhibitors
The  serine-threonine  kinase  mammalian  target  of 
rapamycin  (mTOR)  promotes  protein  translation, 
angiogenesis, proliferation, migration, and metabo-
lism.106 mTOR has two complexes, mTOR complexes 
1 and 2 (mTORC1 and mTORC2). The mTORC1 con-
sists of mTOR, mammalian LST8 (mLST8), proline-
rich Akt substrate 40 (PRAS 40) and raptor.107 Release 
of PRAS 40 leads to mTORC1 activation and phos-
phorylation of eukaryotic initiation factor 4E-binding 
protein (4E-BP1) and S6 kinase 1 (S6K1). Activation 
of 4E-BP1 enhances cell proliferation, survival and 
angiogenesis.108  Phosphorylation  of  S6K1  leads  to 
many important cellular functions including activa-
tion of insulin receptor substrate 1 (IRS-1), eukary-
otic initiation factor 4B, cellular apoptosis, eukaryotic 
elongation factor-2/kinase/mTOR, and glycogen syn-
thase kinase 3.109 Both 4E-BP1 and S6K1 have been 
associated  with  cellular  transformation  and  poor 
prognosis of cancer patients.108,110 The other mTOR 
complex, mTORC2, consists of mTOR, SIN1, and 
mLST8, PRR, and rector.111–115 This complex has been 
shown to activate Akt phosphorylation and has been 
implicated in cellular migration and apoptosis.111,116
Inhibiting mTOR’s mediated PI3K/Akt signaling 
pathway  abolishes  cellular  proliferative  responses 
and causes cell cycle arrest. As PI3K/Akt overactivity 
has been identified in a number of breast cancers,117 
rapamycin and its analogs temsirolimus, everolimus, 
and deforolimus, are undergoing clinical evaluation 
in TNBC treatment.
iGF-1R
Insulin-like growth factor I receptor belongs to a class 
of tyrosine kinase receptors that contribute to prolifer-
ative control, apoptosis, angiogenesis and tumor inva-
sion.118 Expressed in 29%–36% of all TNBC tumors119 
has been   implicated in the activation of the PI3 K/Akt 
proliferative pathway in breast cancer.120,122 Preclinical 
studies in TNBC tumor grafts treated with anti-IGF-IR/
InsR dual TKI and chemotherapy have demonstrated 
complete tumor regression.123 Drugs targeting IGF-1R 
are of two types: monoclonal antibodies specific for 
IGF-1R (eg, cixutumumab, ganitumab, figitumumab) 
and TKIs (linsitinib, XL-228). Drugs of both types 
are being investigated in treating TNBC.
Androgen receptor (AR) inhibition
Preclinical in-vitro studies demonstrated that andro-
gens  can  induce  proliferative  changes  in  breast 
cancer cell lines and promote tumorigenesis in animal 
  models by androgen receptor stimulation.124 Doane 
and   colleagues examined MDA-MB-453, a cell line 
with the same biomarker phenotype as TNBC and 
found that androgen enhanced growth of this cells 
line  was  ER-independent  and  AR-dependent.125 Minami et al
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10%–35% of TNBC express androgen receptors,126,127 
and it has been suggested that a subset of TNBC cases 
may  benefit  from  the  addition  of  androgen  block-
ade to their therapy.128 Bicalutamide, a nonsteroidal 
competitive androgen inhibitor, is used in the treat-
ment of advanced prostate cancer, but until recently, 
its anticancer effects were not tested in women.
Heat shock protein (Hsp) 90 inhibition
Hsp 90 is a chaperone protein that is widely expressed 
in breast cancer. It stabilizes client oncogenic proteins 
and contributes to the survival of tumor cells. In a pre-
clinical study, Caldas-Lopes and colleagues demon-
strated that the Hsp 90 inhibitor PU-HTI suppressed 
TNBC xenograft growth in vivo, showing both partial 
tumor regression and complete response.129 In vitro, 
Hsp 90 inhibition has been shown to 1) down-regulate 
members of the Ras/Raf/MAPK pathway and G 2-M 
phase to suppress Hsp 90 dependent tumor prolifera-
tion, 2) degrade the activated Akt and Bcl-XL, thus 
inducing apoptosis, and 3) inhibit the activated NF-KB, 
Akt, ERK2, Tyk2, and PKC, therefore reducing the 
invasive potential of TNBC. Their findings suggest 
that Hsp 90 may be an effective and pluripotent target 
for TNBC therapy.
clinical studies in TnBc Management 
Options
Chemotherapy
Until  recently,  due  to  a  lack  of  a  specific  target, 
systemic treatment options for TNBC were limited 
to cytotoxic chemotherapy. TNBC, when compared 
with other phenotypes, were found to have a more 
favorable outcome after chemotherapy.14 Shorter OS 
and disease-free intervals have been seen in patients 
who  did  not  receive  adjuvant  chemotherapy.9  In 
addition, TNBC patients are known to have a greater 
pathologic  complete  response  (pCR)  rate  when 
compared  with  non-TNBC  patients.130  But  does 
chemoresponsiveness lead to better overall survival? 
The NSABP B-18 and B-27 trials, which looked at a 
combination of neoadjuvant and adjuvant regimens 
of doxorubicin and cyclophosphamide (AC) with or 
without docetaxel, found that patients who achieved 
a pCR continued to have superior DFS and OS when 
compared  with  patients  who  did  not.131  However, 
there  exists  what  is  known  as  the  “triple-negative 
paradox”: while TNBC may be more chemosensitive, 
the poor prognosis associated with the disease can be 
explained by the high relapse rate in those patients 
who are unable to achieve a pCR.132
Many studies examining the timing of chemother-
apy in the treatment of breast cancer have found that 
neoadjuvant therapy is equivalent to adjuvant ther-
apy in OS and disease-free survival. A meta-analysis 
of nine randomized studies by Mauri et al however, 
found that neoadjuvant therapy was associated with an 
increased risk of loco-regional recurrence in patients 
treated with radiation therapy without surgery.133 As 
this meta-analysis lacked a subset for TNBC patients, 
further investigation into the issue of neoadjuvant ver-
sus adjuvant therapy for TNBC patients is warranted.
The specific scheduling of chemotherapy may also 
be important in treating TNBC.130,134 Dose-dense (in 
which intertreatment intervals are shortened) and/or 
metronomic scheduling (chronic, low-dose administra-
tion of therapy) have been shown not only to improve 
progression-free  survival  (PFS),  but  also  increase 
pCR;135–137 this in turn could mean   significantly greater 
OS, whereby weekly or bi-weekly AC and paclitaxel 
may greatly benefit TNBC patients. Dose intensification 
may also improve event-free survival and overall sur-
vival in TNBC patients with multiple positive nodes.138
Though trials have yet to demonstrate a clear increase 
in DFS and OS with neoadjuvant chemotherapy, there 
is still a clinical advantage given the   availability of 
tissue and the ability to   correlate potential biomarkers 
with pathologic response. More experimental neoad-
juvant regimens including platinum salts paired with 
a taxane and excluding the use of anthracyclines, have 
shown to achieve high pCR rates in TNBC but choice 
of drug in this setting has yet to be established.139,140
In the adjuvant setting, anthracyclines and taxanes 
remain the standard of care for TNBC patients with 
operable,  node-positive  breast  cancer.141–143  Relative 
anthracycline sensitivity and taxane-resistance among 
TNBC patients may hinge on BRCA-1 function. The 
loss of BRCA-1 is associated with sensitivity to DNA-
damaging chemotherapy as well as resistance to spindle 
poisons, such as taxanes and vinca alkaloids.144 This is 
relevant not only for carriers of the BRCA-1 mutation 
but  for  patients  with  sporadically-occurring  TNBC 
whose  tumors  have  DNA  repair  defects  similar  to 
BRCA-1 associated tumors; in this population, it has 
been demonstrated that anthracycline sensitivity and 
taxane-resistance  may  be  predicted  by  a  BRCA-1 Management options in TNBC
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associated  expression  signature.145  A  recent  study 
showed that the classical regimen of cyclophosphamide, 
methotrexate, and fluorouracil (CMF) had a greater 
benefit in node-negative TNBC patients than in patients 
with  hormone-receptor  positive  or  HER-2  positive/
hormone-receptor negative disease, suggesting CMF 
may be a good choice for adjuvant therapy in certain 
populations.146 Currently, there is no standard first line 
agent to recommend for use in metastatic disease.
platinum salts
The use of platinum salts in the neoadjuvant setting 
is promising, as TNBC patients undergoing regimens 
containing platinum salts with or without other agents 
showed  pathological  complete  response  rates  rang-
ing  from  15%–83%.78,83,84,132 The  best  partner  agents 
for platinum salts in the adjuvant setting has yet to be 
determined; regimens combining platinum salts with 
epirubicin, adriamycin, taxol, and taxotere all showed 
high pCR rates in TNBC patients.78,147,148 Pairing neoad-
juvant cisplatin with bevacizumab did show 15% com-
plete  pathologic  response  in TNBC  patients,  though 
toxicity limited completion of therapy in about 10% of 
patients.149 The tumor response to platinum-based drugs 
in metastatic TNBC is also being evaluated.85 Mature 
data from prospective randomized controlled trials, such 
as NCT00532727, a phase III randomized trial compar-
ing carboplatin and docetaxel as first-line treatment in 
metastatic and recurrent TNBC, and CALGB 40603, 
which is testing neoadjuvant carboplatin and taxane 
therapy in stage II and III TNBC, are not yet available 
(CALGB NCT00861705). While the role of this class 
of drug in treating patients with TNBC is being actively 
pursued, routine use of  platinum-containing regimens in 
patients with early-stage TNBC is not recommended.
Anti-tubulin drugs
Taxanes
The taxanes include paclitaxel and   docetaxel and has 
proven effective in all breast cancer types in both the 
neoadjuvant and adjuvant setting.78,85 TNBC has shown 
to have a better response to   taxane-containing regimens 
than to chemotherapy without taxanes142 and to have a 
significantly better response rate to neoadjuvant taxane 
treatment.85,150,151 Whether they prove more effective 
in TNBC patients in the adjuvant setting than other 
breast cancer subtypes is questionable. Subset analysis 
from  the  BCIRG001  trial  (docetaxel,  doxorubicin, 
and cyclophosphamide vs. fluorouracil, doxorubicin 
and cyclophosphamide) found that the benefits of the 
docetaxel-containing  regimen  were  independent  of 
hormone receptor status.142 Similarly equivocal results 
between hormone-receptor subgroups were obtained 
in the NSABP B28 trial, which looked at doxorubicin 
and cyclophosphamide with or without paclitaxel.152
ixabepilone
Its antitumor activity in TNBC has been demonstrated 
both when used as monotherapy or in combination 
with  capecitabine.  When  administered  as  mono-
therapy, ixabepilone induced a higher pCR in TNBC 
groups  (26%–28%)  when  compared  to  non-TNBC 
patients  or  to  the  overall  study  patient  population 
(15%–18%).89,153–155
Several phase II and III trials have also looked at 
ixabepilone’s efficacy when paired with capecitabine, 
a second-line therapy widely used in anthracycline 
and taxane-resistant disease. Analysis of pooled data 
from  these  trials  found  that  overall  response  rate 
(ORR) (31 vs. 15%) and PFS (4.2 vs. 1.7 months) 
were  improved  in  TNBC  patients  who  received 
combination therapy as opposed to those who received 
single-agent capecitabine.156
Ongoing trials are examining ixabepilone activity 
in combination with sunitinib (as first-line therapy 
in TNBC patients), cetuximab (in metastatic TNBC 
patients),  and  in  direct  comparison  to  docetaxel 
and  paclitaxel-containing  regimens.153  Ixabepilone 
has been shown to have a manageable safety pro-
file, with neutropenia, sensory neuropathy, fatigue, 
arthralgias, myalgias, and stomatitis as its main side 
effects.157
Targeted Therapy
pARp inhibitors
Preclinical  data  on  the  mechanisms  of  PARP 
inhibitors have led to early phase clinical trials in the 
targeted treatment of BRCA-deficient breast cancer 
and  TNBC.  This  class  of  drug  includes  olaparib 
(AZD2281,  KU-0059436),  iniparib  (BSI-201),  and 
veliparib (ABT888). The following PARP inhibitors 
are being studied in various phases of clinical trials 
(Table 1).
Olaparib, an oral PARP 1 and PARP2 inhibitor, is 
active in BRCA-deficient ovarian and breast cancers. 
In phase I and II studies, single agent olaparib has Minami et al
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shown antitumor activity in BRCA-mutation carriers 
with refractory and/or advanced disease. A greater par-
tial response rate to olaparib has been demonstrated in 
TNBC patients than in non-TNBC patients (54% vs. 
29% respectively).158 Toxicities observed were primar-
ily grade 1 and 2 and were similar to those observed 
with  conventional  chemotherapy  (fatigue,  nausea, 
vomiting, anemia).159
Encouraging as these results are, it still remains 
unclear if olaparib is effective outside the BRCA-
  associated cancer. Canadian study 20, a phase II trial 
looking  at  four  cohorts  of  patients  with  advanced 
breast or ovarian disease, closed the arm of sporadic 
TNBC patients as no response to olaparib treatment 
was seen.160
The  efficacy  of  olaparib  in  combination  with 
conventional  chemotherapy  agents  has  yet  to  be 
determined.  Concerning  toxicity  patterns  (mainly 
grade 2–4 neutropenia) resulted when the drug was 
paired  with  paclitaxel  in  the  treatment  of  meta-
static TNBC.161 Given pre-clinical data that PARP1 
inhibition  may  potentiate  the  effects  of    platinum 
compounds,162 olaparib is now being tested in combi-
nation with carboplatin and cisplatin in TNBC. Safety 
data from these trials will be important in determin-
ing olaparib’s therapeutic place in TNBC.
Iniparib (BSI 201) is a PARP 1 inhibitor admin-
istered  intravenously.  The  addition  of  iniparib  to 
gemcitabine and carboplatin in a phase II study in met-
astatic TNBC prolonged the median overall   survival 
from 7.7 months to 12.3 month, translating to a 43% 
reduction in the risk of death (HR = 0.57, P = 0.01). 
Median PFS in the iniparib group was 5.9 months 
compared to 3.6 months for the chemotherapy group 
(HR = 0.59, P = 0.01). No significant difference in 
adverse events was seen between the groups.163
These  promising  results  paved  the  way  for  a 
phase III study to evaluate OS and PFS in metastatic 
TNBC (NCT00938652). 519 women with metastatic 
TNBC  were  randomized  to  receive  chemotherapy 
(gemcitabine and carboplatin) with or without iniparib. 
The study admittedly failed to meet the pre-specified 
criteria for significance for its co-primary endpoints 
of OS and PFS. There was, however, an improvement 
in  OS  and  PFS  for  patients  treated  in  the  second 
and third-line. The safety analysis indicated that the 
addition of iniparib did not add to the toxicity profile 
of gemcitabine and carboplatin [JC, Sanofi-Aventis 
press release, January 2011]. The use of iniparib in 
TNBC is currently being tested in the neoadjuvant 
setting (NCT00813956, NCT01204125), and in the 
treatment of brain metastases (NCT01173497).
Veliparib (ABT888), an oral PARP 1 and PARP 
2 inhibitor, is also being investigated. It has shown 
to be well tolerated in combination with metronomic 
cyclophosphamide and to have activity in TNBC.164 
Veliparib with temozolomide, an agent found to be 
synergistic in breast cancer xenograft models, was 
shown  to  have  activity  in  patients  with  metastatic 
breast cancer.165 Though the preliminary data from 
this phase II trial did not include a TNBC subgroup 
analysis,  full  accrual  and  final  efficacy  results  are 
pending.
Whether  all  TNBC  patients  will  benefit  from 
PARP-inhibitors or if only a portion of  TNBC patients, 
such as BRCA-deficient tumors, will have clinical 
improvement beyond chemotherapy alone remains to 
be seen.166 The clinical utility of PARP inhibitors may 
become better realized if predictive biomarkers can 
be identified.158
Anti-angiogenic agents
Anti-vEGF
Numerous  studies  have  examined    bevacizumab  as 
treatment for metastatic   disease and subset analyses 
suggest that TNBC may have an increased sensitivity 
to anti-angiogenic agents.   Multiple studies looking at 
the addition of   bevacizumab to different chemother-
apy agents have shown an increase in PFS in TNBC 
patients.167,168 Several multicenter randomized trials, 
including the   Cancer and Leukemia Group B (CALGB) 
40503  and  National  Surgical Adjuvant  Breast  and 
Bowel Project (NSABP)-B40 studies, hope to gather 
more data on the effect of bevacizumab on TNBC. 
However, as Greenberg and Rugo pointed out, all trials 
to date have used PFS as an endpoint and an improve-
ment in OS has yet to be shown.100 In late 2010, the 
FDA began the process to remove breast cancer as 
an indication from the Avastin label not only due to 
a lack of efficacy, but safety. A 2011 meta-analysis in 
JAMA highlighted the dangers of the drug, finding 
that compared with chemotherapy alone, the addi-
tion of bevacizumab was associated with an increase 
risk of fatal adverse events (FAEs), the most common Management options in TNBC
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being  hemorrhage  (23.5%),  neutropenia  (12.2%), 
and gastrointestinal tract perforation (7.1%).169 While 
there were differences in relative risk across tumors 
types  and  between  drug  doses  and  combinations, 
it  warned  of  the  possible  increased  risk  of  FAEs, 
especially when pairing bevacizumab with taxanes or 
platinum drugs.
EGFR inhibitors
Cetuximab  as  a  single  agent  appears  to  have  low 
activity in metastatic TNBC and so recent research 
has focused on finding the right therapeutic partner for 
this monoclonal antibody. Cetuximab combined with 
the platinum salts has seen encouraging results. Carey 
et al’s study showed little response in the cetuximab 
alone-group, but patients who received cetuximab with 
carboplatin had an 18% response rate (CR and PR) and 
27% saw clinical benefit (PR or SD . 6 months).170 
The BALI-I trial   demonstrated a response rate of 20% 
in the cetuximab plus cisplatin arm, nearly doubled 
the response rate of cisplatin alone. Overall survival 
data is still forthcoming and though it failed to reach 
its primary endpoint (a response rate of more than 
20% in the combination arm), the findings reinforce 
the idea that anti-EGFR agents may have an impor-
tant role to play in TNBC.171
Adding cetuximab to irinotecan and carboplatin 
resulted in an increased in ORR in the TNBC subset of 
O’Shaughnessy’s phase II trial conducted in patients 
with metastatic disease. A drawback, however, was 
that the primary toxicity of the irinotecan/carboplatin 
combination (diarrhea) was exacerbated in patients 
who received cetuximab.172
Preliminary results of a phase I/II trial of   cetuximab 
in combination with either paclitaxel or docetaxel dem-
onstrated a response (defined as a clinical response, 
decreased  tumor  markers,  or  a  decrease  in  size  of 
metastases) in 9 of 11 patients. The observed toxicity in 
this combination was the cumulative expected toxicity 
of each individual agent.173
Patients who suffer infusion reactions (broncho-
spasm,  stridor,  urticaria,  hypotension,  and  cardiac 
arrest)  to  cetuximab,  a  chimeric  monoclonal  anti-
body, may be treated by panitumumab, a fully human 
anti-EGFR monoclonal antibody.174 This new agent is 
currently under clinical investigation in the setting of 
metastatic TNBC (NCT01009983).
Anti-EGFR tyrosine kinase inhibitors
TKIs showed early promise in pre-clinical studies, 
demonstrating efficacy in treating anti-hormone resis-
tant breast cancer.175 In theory these drugs should be 
very effective in TNBC, given that the proliferation 
of  these  tumors  seemed  to  be  EGFR-dependent.176 
But clinical studies have not supported the hypoth-
esis; single-agent TKI studies were not impressive 
in the heavily pre-treated metastatic population nor 
in  the  ER(−),  EGFR-overexpressing  population.177 
Instead,  the  TKIs  seemed  to  be  more  effective  in 
ER(+), tamoxifen-resistant patients even though the 
EGFR expression in their tumors tends to be low-to-
moderate.178
However, like cetuximab, the key to effective TKI 
use probably lies in treatment combinations. Gefitinib 
paired with carboplatin and docetaxel has been shown 
to  be  synergistic  and  enhance  response  in  TNBC 
cells.179 Inhibitors of ADAM (enzymes involved in 
the activation of EGFR ligands) may also be potential 
partners for TKIs in TNBC treatment. Studies testing 
gefitinib with TMI-002 (a compound that specifically 
inhibits ADAM-17 in breast cancer cell lines), did not 
see any additional benefit when the two agents were 
administered  simultaneously;  gefitinib  treatment 
administered  72  hours  after  the  ADAM  inhibitor, 
however, was more effective, though the difference 
did not reach statistical significance. An un-named 
inhibitor of both ADAM 10 and ADAM 17 has been 
found to reduce cell growth by 91% in pre-clinical 
studies and has also been shown to reduce TNBC’s 
migratory  ability  [EM,  EORTC-NCI-AACR  press 
release, November 2010].
Multi-Tyrosine kinase inhibitors
Dasatinib  and  sunitinib  have  been  tested  mostly 
in  patient  populations  that  have  been  heavily 
pre-treated. A  Phase  II  trial  of  single-agent  dasat-
inib in patients with locally advanced or metastatic 
TNBC and prior anthracycline and/or taxane therapy 
found only modest activity (clinical benefit rate of 
9.3%).180 Candidate genomic markers for dasatinib 
therapy selection have been identified in breast can-
cer patients181 and are currently being tested for clini-
cal utility (NCT00780676).
Sunitinib, a TKI that targets the VEGF-  associated 
TK,  has  been  found  to  elicit  response  in  TNBC Minami et al
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i
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p
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p
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c
l
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n
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c
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d
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o
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o
g
i
c
 
 
r
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e
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p
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o
p
o
r
t
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o
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o
f
 
p
a
t
i
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b
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a
v
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a
f
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b
g
r
o
u
p
 
a
n
a
l
y
s
i
s
 
v
s
.
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b
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p
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p
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p
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b
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x
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p
i
l
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n
e
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c
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B
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p
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c
y
c
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n
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n
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a
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n
e
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h
e
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i
x
a
b
e
p
i
l
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/
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d
a
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c
a
p
e
c
i
t
a
b
i
n
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1
6
5
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–
2
0
0
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m
g
/
m
2
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d
a
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1
–
1
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.
 
S
c
h
e
d
u
l
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B
:
 
i
x
a
b
e
p
i
l
o
n
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8
–
1
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g
/
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d
a
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c
a
p
c
i
t
a
b
i
n
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1
6
5
0
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g
/
m
2
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a
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–
1
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.
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y
c
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1
 
d
a
y
s
O
R
R
t
i
m
e
 
t
o
 
r
e
s
p
o
n
s
e
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d
u
r
a
t
i
o
n
 
o
f
 
 
r
e
s
p
o
n
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e
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p
F
S
O
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
r
a
t
e
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0
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,
 
m
e
d
i
a
n
 
t
i
m
e
-
t
o
-
r
e
s
p
o
n
s
e
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w
e
e
k
s
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m
e
d
i
a
t
i
o
n
 
d
u
r
a
t
i
o
n
 
o
f
 
r
e
s
p
o
n
s
e
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.
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o
n
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m
e
d
i
a
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p
F
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n
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x
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b
e
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n
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c
a
p
e
c
i
t
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a
c
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e
p
t
a
b
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a
f
e
t
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r
o
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l
e
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n
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c
l
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n
i
c
a
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a
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t
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i
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o
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p
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n
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.
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5
2
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0
–
1
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.
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5
2
p
t
s
 
w
i
t
h
 
m
e
a
s
u
r
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a
b
l
e
 
l
o
c
a
l
l
y
 
a
d
v
a
n
c
e
d
 
o
r
 
M
B
C
 
p
r
e
-
t
r
e
a
t
e
d
 
w
i
t
h
 
o
r
 
r
e
s
i
s
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n
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t
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a
n
t
h
r
a
c
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-
c
l
i
n
e
s
 
a
n
d
 
r
e
s
i
s
t
a
n
t
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t
a
x
a
n
e
s
i
x
a
b
e
p
i
l
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/
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p
e
c
i
t
a
b
i
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e
 
2
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g
/
m
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d
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y
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r
 
c
a
p
e
c
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n
e
 
2
5
0
0
 
m
g
/
m
2
,
 
d
a
y
s
 
1
–
1
4
,
 
c
y
c
l
e
 
=
 
2
1
 
d
a
y
s
p
F
S
T
u
m
o
r
 
r
e
s
p
o
n
s
e
 
 
r
a
t
e
,
 
t
i
m
e
 
t
o
 
r
e
s
p
o
n
s
e
,
 
d
u
r
a
t
i
o
n
 
o
f
 
o
v
e
r
a
l
l
 
 
r
e
s
p
o
n
s
e
,
 
 
o
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
p
F
S
 
i
n
 
i
x
a
b
e
p
i
l
o
n
e
 
+
 
c
a
p
c
i
t
a
b
i
n
e
 
v
s
.
 
c
a
p
e
c
i
t
a
b
i
n
e
 
a
l
o
n
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.
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n
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.
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m
o
n
t
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s
.
 
O
b
j
e
c
t
i
v
e
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=
 
3
5
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1
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.
i
x
a
b
e
p
i
l
o
n
e
 
+
 
c
a
p
e
c
i
t
a
b
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n
e
 
d
e
m
o
n
s
t
r
a
t
e
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u
p
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r
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e
f
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c
a
c
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a
p
e
c
i
t
a
b
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n
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i
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t
h
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i
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n
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o
p
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l
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n
1
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n
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e
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h
a
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i
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B
e
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a
c
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z
u
m
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r
 
K
.
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n
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p
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r
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t
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c
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c
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b
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c
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m
g
/
k
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d
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n
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1
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+
 
p
a
c
l
i
t
a
x
e
l
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c
y
c
l
e
 
=
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d
a
y
s
p
F
S
O
S
I
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T
N
B
C
 
p
t
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m
e
d
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a
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p
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n
c
r
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s
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o
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c
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p
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a
c
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p
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c
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c
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.
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p
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c
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c
e
t
a
x
e
l
 
1
0
0
 
m
g
/
m
2
 
p
l
u
s
 
p
l
a
c
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c
e
t
a
x
e
l
 
1
0
0
 
m
g
/
m
2
 
+
 
 
b
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c
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k
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r
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p
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t
i
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r
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t
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e
n
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a
i
l
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a
f
e
t
y
m
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i
n
c
r
e
a
s
e
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r
o
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.
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k
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c
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B
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a
c
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c
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o
m
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c
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B
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h
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o
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i
t
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c
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a
x
e
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p
l
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c
e
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q
u
a
l
l
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f
f
e
c
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v
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a
t
i
e
n
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o
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u
l
a
t
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o
n
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a
c
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b
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2
3
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p
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s
 
w
/
L
R
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M
B
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p
r
e
v
i
o
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s
l
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u
n
t
r
e
a
t
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b
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c
h
e
m
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h
e
r
a
p
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C
a
p
e
c
i
t
a
b
i
n
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2
0
0
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m
g
/
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o
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d
a
y
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n
a
b
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p
a
c
l
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a
x
e
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2
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/
m
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d
o
c
e
t
a
x
e
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–
1
0
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/
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o
x
o
r
u
b
i
c
i
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o
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e
p
i
r
u
b
i
c
i
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o
m
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o
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q
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w
e
e
k
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o
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c
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d
m
i
n
i
s
t
e
r
e
d
 
a
t
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m
g
/
k
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q
3
w
e
e
k
s
p
F
S
O
S
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y
e
a
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s
u
r
v
i
v
a
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r
a
t
e
,
 
o
b
j
e
c
t
i
v
e
 
 
r
e
s
p
o
n
s
e
 
r
a
t
e
,
 
d
u
r
a
t
i
o
n
 
o
f
 
o
b
j
e
c
t
i
v
e
 
 
r
e
s
p
o
n
s
e
,
 
 
s
a
f
e
t
y
m
p
F
S
 
i
n
c
r
e
a
s
e
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f
r
o
m
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i
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h
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C
a
p
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c
o
h
o
r
t
 
a
n
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f
r
o
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8
.
2
 
t
o
 
1
4
.
5
 
m
o
 
i
n
 
t
a
x
a
n
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/
a
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t
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r
a
c
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l
i
n
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o
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)Management options in TNBC
Breast Cancer: Basic and Clinical Research 2011:5  189
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l
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r
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a
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p
a
t
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e
n
t
s
p
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o
p
u
l
R
e
g
i
m
e
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p
r
i
m
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r
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n
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o
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n
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e
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d
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r
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n
d
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i
n
t
R
e
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u
l
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c
o
n
c
l
u
s
i
o
n
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e
f
e
r
e
n
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e
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h
a
s
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i
/
i
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l
a
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a
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i
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A
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D
e
n
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.
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C
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2
0
1
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2
8
:
1
0
1
8
.
1
9
M
e
t
 
T
N
B
C
 
b
r
e
a
s
t
 
 
C
A
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#
1
 
p
r
i
o
r
 
 
m
e
t
 
b
r
e
a
s
t
 
T
x
O
l
a
p
a
r
i
b
 
2
0
0
 
m
g
 
p
O
 
B
i
D
 
+
 
 
p
a
c
l
i
t
a
x
e
l
 
q
w
e
e
k
 
f
o
r
 
3
 
o
f
 
4
 
w
k
s
p
h
a
s
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i
 
o
b
j
e
c
t
i
v
e
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d
e
t
e
r
m
i
n
e
 
 
s
a
f
e
t
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a
n
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t
o
l
e
r
a
b
i
l
i
t
y
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f
o
l
l
o
w
e
d
 
b
y
 
p
h
a
s
e
 
i
i
 
t
r
i
a
l
 
1
2
/
1
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a
t
i
e
n
t
s
 
h
a
d
 
G
r
a
d
e
 
1
–
4
 
n
e
u
t
r
o
p
e
n
i
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o
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p
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y
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a
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n
e
u
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e
n
i
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d
e
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i
t
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G
C
S
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a
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c
o
n
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r
m
e
d
 
P
R
,
 
1
0
 
p
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c
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n
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u
n
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o
n
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r
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i
o
n
 
o
f
 
b
e
v
a
c
i
z
u
m
a
b
 
b
u
t
 
T
N
B
C
 
s
u
b
-
g
r
o
u
p
 
a
n
a
l
y
s
i
s
 
s
h
o
w
e
d
 
g
r
e
a
t
e
r
 
r
a
t
e
s
 
o
f
 
p
C
R
.
1
9
7
e
G
F
R
 
i
n
h
i
b
i
t
o
r
s
p
h
a
s
e
 
i
i
 
 
c
e
t
u
x
i
m
a
b
 
 
O
’
S
h
a
u
g
h
n
e
s
s
y
 
 
J
.
 
B
r
e
a
s
t
 
 
C
a
n
c
 
R
e
s
 
 
T
r
e
a
t
 
2
0
0
7
;
 
1
0
6
 
(
S
u
p
p
l
 
1
)
,
 
 
a
b
s
t
r
a
c
t
 
3
0
8
.
1
6
3
M
e
t
 
b
r
e
a
s
t
 
C
A
,
 
p
r
i
o
r
 
r
e
g
i
m
e
n
 
e
l
i
g
i
r
i
n
o
t
e
c
a
n
 
+
 
C
a
r
b
o
p
l
a
t
i
n
 
+
/
−
 
C
e
t
u
x
i
m
a
b
.
 
i
r
i
n
o
t
e
c
a
n
 
 
9
0
 
m
g
/
m
2
 
f
o
l
l
o
w
e
d
 
b
y
 
C
a
r
b
o
p
l
a
t
i
n
 
A
U
C
 
2
 
d
a
y
s
 
1
,
 
8
 
o
f
 
2
1
-
d
a
y
 
c
y
c
l
e
.
 
C
e
t
u
x
i
m
a
b
 
4
0
0
 
m
g
/
m
2
 
d
o
s
e
 
1
 
t
h
e
n
 
2
5
0
 
m
g
/
m
2
 
w
e
e
k
l
y
 
 
t
h
e
r
e
a
f
t
e
r
O
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
r
a
t
e
S
e
c
o
n
d
a
r
y
 
e
n
d
p
t
:
 
p
F
S
,
 
O
S
,
 
s
a
f
e
t
y
p
r
e
l
i
m
i
n
a
r
y
 
a
n
a
l
y
s
i
s
:
 
3
9
%
 
o
f
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
c
e
t
u
x
i
m
a
b
 
h
a
d
 
o
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
c
o
m
p
a
r
e
d
 
t
o
 
1
9
%
 
w
h
o
 
r
e
c
’
d
 
c
h
e
m
o
 
o
n
l
y
.
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
c
e
t
u
x
i
m
a
b
 
h
a
d
 
g
r
e
a
t
e
r
 
i
n
c
i
d
e
n
c
e
 
o
f
 
g
r
a
d
e
 
3
–
4
 
t
o
x
i
c
i
t
i
e
s
 
c
o
m
p
a
r
e
d
 
t
o
 
c
h
e
m
o
 
o
n
l
y
 
c
o
h
o
r
t
p
r
e
l
i
m
i
n
a
r
y
 
a
n
a
l
y
s
i
s
 
s
u
g
g
e
s
t
s
 
t
h
a
t
 
a
d
d
i
t
i
o
n
 
o
f
 
c
e
t
u
x
i
m
a
b
 
t
o
 
i
r
i
n
o
t
e
c
a
n
-
c
a
r
b
o
p
l
a
t
i
n
 
m
a
y
 
i
m
p
r
o
v
e
 
a
n
t
i
t
u
m
o
r
 
a
c
t
i
v
i
t
y
 
b
u
t
 
i
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
g
r
e
a
t
e
r
 
i
n
c
i
d
e
n
c
e
 
o
f
 
t
o
x
i
c
i
t
i
e
s
.
1
6
8
p
h
a
s
e
 
i
i
 
 
c
e
t
u
x
i
m
a
b
 
 
(
T
B
c
R
c
 
0
0
1
)
 
 
C
a
r
e
y
 
L
A
.
 
J
C
O
 
 
2
0
0
8
;
2
6
 
 
(
M
a
y
 
2
0
 
S
u
p
p
l
)
,
 
 
a
b
s
t
r
a
c
t
 
1
0
0
9
.
1
0
2
M
e
t
 
T
N
B
C
,
 
 
#
3
 
p
r
i
o
r
 
r
e
g
i
m
e
n
C
e
t
u
x
i
m
a
b
 
+
/
−
 
C
a
r
b
o
p
l
a
t
i
n
 
C
a
r
b
o
p
l
a
t
i
n
 
A
U
C
 
2
 
(
Q
w
k
 
×
 
3
,
 
t
h
e
n
 
1
 
w
k
 
o
f
f
)
.
 
C
e
t
u
x
i
m
a
b
 
4
0
0
 
m
g
/
m
2
,
 
t
h
e
n
 
2
5
0
 
m
g
/
m
2
 
Q
w
k
.
 
p
t
s
 
r
a
n
d
o
m
i
z
e
d
 
t
o
 
C
e
t
u
x
i
m
a
b
 
a
l
o
n
e
 
h
a
d
 
C
a
r
b
o
p
l
a
t
i
n
 
a
d
d
e
d
 
u
p
o
n
 
p
r
o
g
r
e
s
s
i
o
n
O
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
r
a
t
e
 
 
(
R
R
,
 
C
R
+
p
R
)
 
C
e
t
u
x
i
m
a
b
 
a
l
o
n
e
 
(
N
 
=
 
3
1
)
,
 
C
e
t
u
x
i
m
a
b
 
+
 
C
a
r
b
o
p
l
a
t
i
n
 
(
N
 
=
 
7
1
)
.
 
8
7
%
 
r
e
c
’
d
 
p
r
i
o
r
 
a
d
j
u
v
 
c
h
e
m
o
,
 
5
4
%
 
r
e
c
’
d
 
p
r
i
o
r
 
c
h
e
m
o
 
f
o
r
 
M
B
C
.
 
C
e
t
u
x
i
m
a
b
 
a
l
o
n
e
:
 
p
R
 
6
%
,
 
S
D
 
4
%
,
 
c
l
i
n
i
c
a
l
 
b
e
n
e
fi
t
 
(
C
B
 
=
 
p
R
 
o
r
 
S
D
 
.
 
6
 
m
o
s
)
 
=
 
1
0
%
;
 
C
e
t
u
x
i
m
a
b
 
+
 
C
a
r
b
o
p
l
a
t
i
n
:
 
R
R
 
1
8
%
,
 
S
D
 
9
%
,
 
C
B
 
2
7
%
.
 
P
R
 
d
i
d
 
n
o
t
 
d
i
f
f
e
r
 
b
y
 
l
i
n
e
 
o
f
 
T
x
:
 
1
5
%
 
1
s
t
-
l
i
n
e
,
 
3
1
%
 
2
n
d
-
l
i
n
e
,
 
1
7
%
 
3
r
d
 
l
i
n
e
.
 
M
e
d
i
a
n
 
p
F
S
 
=
 
2
 
m
o
n
t
h
s
.
 
R
e
g
i
m
e
n
 
w
a
s
 
t
o
l
e
r
a
b
l
e
.
 
G
r
e
a
t
e
r
 
i
n
c
i
d
 
o
f
 
g
r
a
d
e
 
3
–
4
 
A
E
’
s
 
n
o
t
e
d
 
i
n
 
C
e
t
u
x
i
m
a
b
 
+
 
c
a
r
b
o
p
l
a
t
i
n
 
a
r
m
C
e
t
u
x
i
m
a
b
 
a
l
o
n
e
 
i
s
 
w
e
l
l
 
t
o
l
e
r
a
t
e
d
 
b
u
t
 
h
a
s
 
l
o
w
 
a
c
t
i
v
i
t
y
 
i
n
 
m
e
t
 
T
N
B
C
.
 
M
a
n
y
 
p
t
s
 
p
r
o
g
r
e
s
s
e
d
 
r
a
p
i
d
l
y
.
1
6
6
p
h
a
s
e
 
i
i
 
 
c
e
t
u
x
i
m
a
b
 
 
(
B
A
L
I
-
1
)
 
 
B
a
s
e
l
g
a
 
J
.
 
 
A
n
n
 
O
n
c
o
l
 
2
0
1
0
;
 
 
2
1
 
(
S
u
p
p
l
 
8
)
:
 
 
a
b
s
t
r
a
c
t
 
2
7
4
0
.
1
7
3
M
e
t
 
T
N
B
C
,
 
 
#
1
 
p
r
i
o
r
 
r
e
g
i
m
e
n
 
f
o
r
 
m
e
t
 
d
i
s
e
a
s
e
C
i
s
p
l
a
t
i
n
 
(
C
D
D
p
)
 
+
/
−
 
C
e
t
u
x
i
m
a
b
O
v
e
r
a
l
l
 
r
e
s
p
o
n
s
e
 
(
O
R
R
)
S
e
c
o
n
d
a
r
y
 
e
n
d
p
t
:
 
p
F
S
,
 
O
S
,
 
s
a
f
e
t
y
C
e
t
u
x
i
m
a
b
 
+
 
C
D
D
p
 
(
N
 
=
 
1
1
5
)
,
 
C
D
D
p
 
a
l
o
n
e
 
(
N
 
=
 
5
8
)
.
 
2
7
%
 
o
f
 
p
t
s
 
i
n
 
b
o
t
h
 
a
r
m
s
 
h
a
d
 
p
r
i
o
r
 
c
h
e
m
o
t
h
e
r
a
p
y
 
a
n
d
 
w
e
r
e
 
w
e
l
l
 
b
a
l
a
n
c
e
d
 
f
o
r
 
p
S
.
 
O
R
R
 
w
a
s
 
2
0
%
 
i
n
 
C
e
t
u
x
i
m
a
b
 
+
 
C
D
D
P
 
a
r
m
 
v
s
.
 
1
0
.
3
3
%
 
w
i
t
h
 
C
D
D
p
 
a
l
o
n
e
.
 
p
F
S
 
w
a
s
 
3
.
7
 
m
o
 
w
i
t
h
 
c
e
t
u
x
i
m
a
b
+
C
D
D
p
 
v
s
.
 
1
.
5
 
m
o
 
w
i
t
h
 
C
D
D
p
 
a
l
o
n
e
.
 
G
r
a
d
e
 
3
/
4
 
A
E
’
s
 
n
o
t
e
d
 
i
n
 
.
5
%
 
o
f
 
p
t
s
:
 
a
c
n
e
-
l
i
k
e
 
r
a
s
h
 
(
C
e
t
u
x
i
m
a
b
 
+
 
C
D
D
p
 
o
n
l
y
)
,
 
n
e
u
t
r
o
p
e
n
i
a
,
 
f
a
t
i
g
u
e
,
 
d
y
s
p
n
e
a
.
A
d
d
i
t
i
o
n
 
o
f
 
C
e
t
u
x
i
m
a
b
 
t
o
 
C
D
D
p
 
i
n
c
r
e
a
s
e
d
 
O
R
R
 
a
n
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
i
m
p
r
o
v
e
d
 
p
F
S
 
w
i
t
h
o
u
t
 
a
n
y
 
n
e
w
 
s
a
f
e
t
y
 
c
o
n
c
e
r
n
s
.
1
6
7
p
h
a
s
e
 
i
/
i
i
 
 
c
e
t
u
x
i
m
a
b
 
 
N
e
c
h
u
s
h
t
a
n
 
H
.
 
 
J
C
O
 
2
0
0
9
;
2
7
 
 
(
S
u
p
p
l
)
,
 
a
b
s
t
r
a
c
t
 
 
1
2
0
1
8
.
1
2
M
e
t
 
T
N
B
C
,
 
 
#
2
 
p
r
i
o
r
 
r
e
g
i
m
e
n
 
 
f
o
r
 
m
e
t
 
d
i
s
e
a
s
e
T
a
x
a
n
e
 
(
p
a
c
l
i
t
a
x
e
l
 
8
0
 
m
g
/
m
2
 
o
r
 
D
o
c
e
t
a
x
e
l
 
 
3
0
 
m
g
/
m
2
)
 
+
 
C
e
t
u
x
i
m
a
b
 
Q
w
k
 
(
d
o
s
e
 
n
o
t
 
s
p
e
c
i
fi
e
d
)
C
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
 
p
r
e
l
i
m
i
n
a
r
y
 
a
n
a
l
y
s
i
s
:
 
R
e
s
p
o
n
s
e
 
(
c
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
,
 
t
u
m
o
r
 
m
a
r
k
e
r
 
d
e
c
r
,
 
d
e
c
r
 
i
n
 
m
e
t
 
s
i
z
e
)
 
n
o
t
e
d
 
i
n
 
9
/
1
1
 
p
t
s
 
(
1
 
p
t
 
n
o
n
-
e
v
a
l
)
.
 
3
 
p
t
s
 
d
e
v
e
l
 
b
r
a
i
n
 
m
e
t
s
 
d
u
r
i
n
g
 
T
x
.
 
9
 
p
t
s
 
h
a
d
 
p
r
i
o
r
 
t
a
x
a
n
e
 
T
x
.
S
o
m
e
 
i
m
p
r
e
s
s
i
v
e
 
c
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
s
 
 
n
o
t
e
d
 
e
v
e
n
 
i
n
 
t
a
x
a
n
e
 
p
r
e
-
t
r
e
a
t
e
d
 
p
t
s
.
 
T
o
x
i
c
i
t
y
 
i
s
 
c
u
m
u
l
a
t
e
d
 
e
x
p
e
c
t
e
d
 
t
o
x
i
c
i
t
y
 
 
o
f
 
e
a
c
h
 
o
f
 
t
h
e
 
a
g
e
n
t
s
.
1
6
9
p
h
a
s
e
 
i
i
 
 
e
r
l
o
t
i
n
i
b
 
 
D
i
c
k
l
e
r
 
M
N
.
 
 
B
r
e
a
s
t
 
C
a
n
c
e
r
 
 
R
e
s
 
T
r
e
a
t
.
 
2
0
0
9
;
 
 
1
1
5
:
1
1
5
–
2
1
.
4
7
p
t
s
 
w
/
l
o
c
a
l
l
y
 
a
d
v
a
n
c
e
d
 
o
r
 
M
B
C
 
w
/
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
 
d
u
r
i
n
g
 
o
r
 
a
f
t
e
r
 
t
h
e
r
a
p
y
 
w
i
t
h
 
a
n
 
a
n
t
h
r
a
c
y
c
l
i
n
e
,
 
t
a
x
a
n
e
,
 
a
n
d
 
c
a
p
e
c
i
t
a
b
i
n
e
 
(
c
o
h
o
r
t
 
1
)
,
 
o
r
 
d
u
r
i
n
g
 
o
r
 
a
f
t
e
r
 
t
h
e
r
a
p
y
 
w
i
t
h
 
o
n
e
 
c
h
e
m
o
-
t
h
e
r
a
p
y
 
r
e
g
i
m
e
n
 
(
c
o
h
o
r
t
 
2
)
E
r
l
o
t
i
n
i
b
 
1
5
0
 
m
g
 
p
O
 
q
d
a
y
R
e
s
p
o
n
s
e
 
r
a
t
e
S
a
f
e
t
y
,
 
t
i
m
e
 
t
o
 
p
r
o
-
g
r
e
s
s
i
o
n
,
 
s
u
r
v
i
v
a
l
O
n
e
 
p
t
 
i
n
 
e
a
c
h
 
c
o
h
o
r
t
 
h
a
d
 
p
R
.
E
r
l
o
t
i
n
i
b
 
h
a
d
 
m
i
n
i
m
a
l
 
a
c
t
i
v
i
t
y
 
i
n
 
 
u
n
s
e
l
e
c
t
e
d
 
p
r
e
v
i
o
u
s
l
y
 
t
r
e
a
t
e
d
 
w
o
m
e
n
 
 
w
i
t
h
 
a
d
v
a
n
c
e
d
 
B
C
1
7
2
(
C
o
n
t
i
n
u
e
d
)Management options in TNBC
Breast Cancer: Basic and Clinical Research 2011:5  191
T
a
b
l
e
 
1
.
 
(
C
o
n
t
i
n
u
e
d
)
T
r
i
a
l
T
o
t
a
l
 
p
a
t
i
e
n
t
s
p
t
 
p
o
p
u
l
R
e
g
i
m
e
n
p
r
i
m
a
r
y
 
e
n
d
p
o
i
n
t
s
e
c
o
n
d
a
r
y
 
 
e
n
d
p
o
i
n
t
R
e
s
u
l
t
s
c
o
n
c
l
u
s
i
o
n
s
R
e
f
e
r
e
n
c
e
p
h
a
s
e
 
i
i
i
 
 
B
e
v
a
c
i
z
u
m
a
b
 
 
v
o
n
 
M
i
n
c
k
w
i
t
z
 
G
.
 
S
A
B
C
S
.
 
2
0
1
0
;
 
 
a
b
s
t
r
a
c
t
 
S
4
–
6
.
1
9
4
8
E
a
r
l
y
 
o
r
 
l
o
c
a
l
l
y
 
 
a
d
v
a
n
c
e
d
 
H
E
R
2
-
 
n
e
g
a
t
i
v
e
 
b
r
e
a
s
t
 
c
a
n
c
e
r
e
p
i
r
u
b
i
c
i
n
 
9
0
 
m
g
/
m
2
 
+
 
c
y
c
l
o
p
h
o
s
p
h
a
m
i
d
e
 
 
6
0
0
 
m
g
/
m
2
 
w
i
t
h
 
o
r
 
w
i
t
h
o
u
t
 
b
e
v
a
c
i
z
u
m
a
b
 
1
5
 
m
g
/
k
g
 
q
3
w
e
e
k
s
p
C
R
C
o
m
p
l
i
a
n
c
e
 
 
a
n
d
 
t
o
x
i
c
i
t
y
O
v
e
r
a
l
l
 
p
C
R
 
i
n
 
b
e
v
a
c
i
z
u
m
a
b
-
c
o
n
t
a
i
n
i
n
g
 
a
r
m
 
=
 
1
7
.
5
%
 
v
e
r
s
u
s
 
p
C
R
 
i
n
 
c
h
e
m
o
t
h
e
r
a
p
y
 
w
/
o
u
t
 
b
e
v
a
c
i
z
u
m
a
b
 
=
 
1
5
%
.
 
H
o
w
e
v
e
r
,
 
4
0
%
 
i
n
c
r
e
a
s
e
 
i
n
 
p
C
R
 
i
n
 
T
N
B
C
 
g
r
o
u
p
 
w
/
a
d
d
i
t
i
o
n
 
o
f
 
b
e
v
a
c
i
z
u
m
a
b
.
N
o
 
s
t
a
t
i
s
t
i
c
a
l
 
s
i
g
.
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
o
v
e
r
a
l
l
 
s
t
u
d
y
 
p
o
p
u
l
a
t
i
o
n
 
w
i
t
h
 
a
d
d
i
t
i
o
n
 
o
f
 
b
e
v
a
c
i
z
u
m
a
b
 
b
u
t
 
T
N
B
C
 
s
u
b
-
g
r
o
u
p
 
a
n
a
l
y
s
i
s
 
s
h
o
w
e
d
 
g
r
e
a
t
e
r
 
r
a
t
e
s
 
o
f
 
p
C
R
.
1
9
7
e
G
F
R
 
i
n
h
i
b
i
t
o
r
s
p
h
a
s
e
 
i
i
 
 
c
e
t
u
x
i
m
a
b
 
 
O
’
S
h
a
u
g
h
n
e
s
s
y
 
 
J
.
 
B
r
e
a
s
t
 
 
C
a
n
c
 
R
e
s
 
 
T
r
e
a
t
 
2
0
0
7
;
 
1
0
6
 
(
S
u
p
p
l
 
1
)
,
 
 
a
b
s
t
r
a
c
t
 
3
0
8
.
1
6
3
M
e
t
 
b
r
e
a
s
t
 
C
A
,
 
p
r
i
o
r
 
r
e
g
i
m
e
n
 
e
l
i
g
i
r
i
n
o
t
e
c
a
n
 
+
 
C
a
r
b
o
p
l
a
t
i
n
 
+
/
−
 
C
e
t
u
x
i
m
a
b
.
 
i
r
i
n
o
t
e
c
a
n
 
 
9
0
 
m
g
/
m
2
 
f
o
l
l
o
w
e
d
 
b
y
 
C
a
r
b
o
p
l
a
t
i
n
 
A
U
C
 
2
 
d
a
y
s
 
1
,
 
8
 
o
f
 
2
1
-
d
a
y
 
c
y
c
l
e
.
 
C
e
t
u
x
i
m
a
b
 
4
0
0
 
m
g
/
m
2
 
d
o
s
e
 
1
 
t
h
e
n
 
2
5
0
 
m
g
/
m
2
 
w
e
e
k
l
y
 
 
t
h
e
r
e
a
f
t
e
r
O
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
r
a
t
e
S
e
c
o
n
d
a
r
y
 
e
n
d
p
t
:
 
p
F
S
,
 
O
S
,
 
s
a
f
e
t
y
p
r
e
l
i
m
i
n
a
r
y
 
a
n
a
l
y
s
i
s
:
 
3
9
%
 
o
f
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
c
e
t
u
x
i
m
a
b
 
h
a
d
 
o
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
c
o
m
p
a
r
e
d
 
t
o
 
1
9
%
 
w
h
o
 
r
e
c
’
d
 
c
h
e
m
o
 
o
n
l
y
.
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
c
e
t
u
x
i
m
a
b
 
h
a
d
 
g
r
e
a
t
e
r
 
i
n
c
i
d
e
n
c
e
 
o
f
 
g
r
a
d
e
 
3
–
4
 
t
o
x
i
c
i
t
i
e
s
 
c
o
m
p
a
r
e
d
 
t
o
 
c
h
e
m
o
 
o
n
l
y
 
c
o
h
o
r
t
p
r
e
l
i
m
i
n
a
r
y
 
a
n
a
l
y
s
i
s
 
s
u
g
g
e
s
t
s
 
t
h
a
t
 
a
d
d
i
t
i
o
n
 
o
f
 
c
e
t
u
x
i
m
a
b
 
t
o
 
i
r
i
n
o
t
e
c
a
n
-
c
a
r
b
o
p
l
a
t
i
n
 
m
a
y
 
i
m
p
r
o
v
e
 
a
n
t
i
t
u
m
o
r
 
a
c
t
i
v
i
t
y
 
b
u
t
 
i
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
g
r
e
a
t
e
r
 
i
n
c
i
d
e
n
c
e
 
o
f
 
t
o
x
i
c
i
t
i
e
s
.
1
6
8
p
h
a
s
e
 
i
i
 
 
c
e
t
u
x
i
m
a
b
 
 
(
T
B
c
R
c
 
0
0
1
)
 
 
C
a
r
e
y
 
L
A
.
 
J
C
O
 
 
2
0
0
8
;
2
6
 
 
(
M
a
y
 
2
0
 
S
u
p
p
l
)
,
 
 
a
b
s
t
r
a
c
t
 
1
0
0
9
.
1
0
2
M
e
t
 
T
N
B
C
,
 
 
#
3
 
p
r
i
o
r
 
r
e
g
i
m
e
n
C
e
t
u
x
i
m
a
b
 
+
/
−
 
C
a
r
b
o
p
l
a
t
i
n
 
C
a
r
b
o
p
l
a
t
i
n
 
A
U
C
 
2
 
(
Q
w
k
 
×
 
3
,
 
t
h
e
n
 
1
 
w
k
 
o
f
f
)
.
 
C
e
t
u
x
i
m
a
b
 
4
0
0
 
m
g
/
m
2
,
 
t
h
e
n
 
2
5
0
 
m
g
/
m
2
 
Q
w
k
.
 
p
t
s
 
r
a
n
d
o
m
i
z
e
d
 
t
o
 
C
e
t
u
x
i
m
a
b
 
a
l
o
n
e
 
h
a
d
 
C
a
r
b
o
p
l
a
t
i
n
 
a
d
d
e
d
 
u
p
o
n
 
p
r
o
g
r
e
s
s
i
o
n
O
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
r
a
t
e
 
 
(
R
R
,
 
C
R
+
p
R
)
 
C
e
t
u
x
i
m
a
b
 
a
l
o
n
e
 
(
N
 
=
 
3
1
)
,
 
C
e
t
u
x
i
m
a
b
 
+
 
C
a
r
b
o
p
l
a
t
i
n
 
(
N
 
=
 
7
1
)
.
 
8
7
%
 
r
e
c
’
d
 
p
r
i
o
r
 
a
d
j
u
v
 
c
h
e
m
o
,
 
5
4
%
 
r
e
c
’
d
 
p
r
i
o
r
 
c
h
e
m
o
 
f
o
r
 
M
B
C
.
 
C
e
t
u
x
i
m
a
b
 
a
l
o
n
e
:
 
p
R
 
6
%
,
 
S
D
 
4
%
,
 
c
l
i
n
i
c
a
l
 
b
e
n
e
fi
t
 
(
C
B
 
=
 
p
R
 
o
r
 
S
D
 
.
 
6
 
m
o
s
)
 
=
 
1
0
%
;
 
C
e
t
u
x
i
m
a
b
 
+
 
C
a
r
b
o
p
l
a
t
i
n
:
 
R
R
 
1
8
%
,
 
S
D
 
9
%
,
 
C
B
 
2
7
%
.
 
P
R
 
d
i
d
 
n
o
t
 
d
i
f
f
e
r
 
b
y
 
l
i
n
e
 
o
f
 
T
x
:
 
1
5
%
 
1
s
t
-
l
i
n
e
,
 
3
1
%
 
2
n
d
-
l
i
n
e
,
 
1
7
%
 
3
r
d
 
l
i
n
e
.
 
M
e
d
i
a
n
 
p
F
S
 
=
 
2
 
m
o
n
t
h
s
.
 
R
e
g
i
m
e
n
 
w
a
s
 
t
o
l
e
r
a
b
l
e
.
 
G
r
e
a
t
e
r
 
i
n
c
i
d
 
o
f
 
g
r
a
d
e
 
3
–
4
 
A
E
’
s
 
n
o
t
e
d
 
i
n
 
C
e
t
u
x
i
m
a
b
 
+
 
c
a
r
b
o
p
l
a
t
i
n
 
a
r
m
C
e
t
u
x
i
m
a
b
 
a
l
o
n
e
 
i
s
 
w
e
l
l
 
t
o
l
e
r
a
t
e
d
 
b
u
t
 
h
a
s
 
l
o
w
 
a
c
t
i
v
i
t
y
 
i
n
 
m
e
t
 
T
N
B
C
.
 
M
a
n
y
 
p
t
s
 
p
r
o
g
r
e
s
s
e
d
 
r
a
p
i
d
l
y
.
1
6
6
p
h
a
s
e
 
i
i
 
 
c
e
t
u
x
i
m
a
b
 
 
(
B
A
L
I
-
1
)
 
 
B
a
s
e
l
g
a
 
J
.
 
 
A
n
n
 
O
n
c
o
l
 
2
0
1
0
;
 
 
2
1
 
(
S
u
p
p
l
 
8
)
:
 
 
a
b
s
t
r
a
c
t
 
2
7
4
0
.
1
7
3
M
e
t
 
T
N
B
C
,
 
 
#
1
 
p
r
i
o
r
 
r
e
g
i
m
e
n
 
f
o
r
 
m
e
t
 
d
i
s
e
a
s
e
C
i
s
p
l
a
t
i
n
 
(
C
D
D
p
)
 
+
/
−
 
C
e
t
u
x
i
m
a
b
O
v
e
r
a
l
l
 
r
e
s
p
o
n
s
e
 
(
O
R
R
)
S
e
c
o
n
d
a
r
y
 
e
n
d
p
t
:
 
p
F
S
,
 
O
S
,
 
s
a
f
e
t
y
C
e
t
u
x
i
m
a
b
 
+
 
C
D
D
p
 
(
N
 
=
 
1
1
5
)
,
 
C
D
D
p
 
a
l
o
n
e
 
(
N
 
=
 
5
8
)
.
 
2
7
%
 
o
f
 
p
t
s
 
i
n
 
b
o
t
h
 
a
r
m
s
 
h
a
d
 
p
r
i
o
r
 
c
h
e
m
o
t
h
e
r
a
p
y
 
a
n
d
 
w
e
r
e
 
w
e
l
l
 
b
a
l
a
n
c
e
d
 
f
o
r
 
p
S
.
 
O
R
R
 
w
a
s
 
2
0
%
 
i
n
 
C
e
t
u
x
i
m
a
b
 
+
 
C
D
D
P
 
a
r
m
 
v
s
.
 
1
0
.
3
3
%
 
w
i
t
h
 
C
D
D
p
 
a
l
o
n
e
.
 
p
F
S
 
w
a
s
 
3
.
7
 
m
o
 
w
i
t
h
 
c
e
t
u
x
i
m
a
b
+
C
D
D
p
 
v
s
.
 
1
.
5
 
m
o
 
w
i
t
h
 
C
D
D
p
 
a
l
o
n
e
.
 
G
r
a
d
e
 
3
/
4
 
A
E
’
s
 
n
o
t
e
d
 
i
n
 
.
5
%
 
o
f
 
p
t
s
:
 
a
c
n
e
-
l
i
k
e
 
r
a
s
h
 
(
C
e
t
u
x
i
m
a
b
 
+
 
C
D
D
p
 
o
n
l
y
)
,
 
n
e
u
t
r
o
p
e
n
i
a
,
 
f
a
t
i
g
u
e
,
 
d
y
s
p
n
e
a
.
A
d
d
i
t
i
o
n
 
o
f
 
C
e
t
u
x
i
m
a
b
 
t
o
 
C
D
D
p
 
i
n
c
r
e
a
s
e
d
 
O
R
R
 
a
n
d
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
i
m
p
r
o
v
e
d
 
p
F
S
 
w
i
t
h
o
u
t
 
a
n
y
 
n
e
w
 
s
a
f
e
t
y
 
c
o
n
c
e
r
n
s
.
1
6
7
p
h
a
s
e
 
i
/
i
i
 
 
c
e
t
u
x
i
m
a
b
 
 
N
e
c
h
u
s
h
t
a
n
 
H
.
 
 
J
C
O
 
2
0
0
9
;
2
7
 
 
(
S
u
p
p
l
)
,
 
a
b
s
t
r
a
c
t
 
 
1
2
0
1
8
.
1
2
M
e
t
 
T
N
B
C
,
 
 
#
2
 
p
r
i
o
r
 
r
e
g
i
m
e
n
 
 
f
o
r
 
m
e
t
 
d
i
s
e
a
s
e
T
a
x
a
n
e
 
(
p
a
c
l
i
t
a
x
e
l
 
8
0
 
m
g
/
m
2
 
o
r
 
D
o
c
e
t
a
x
e
l
 
 
3
0
 
m
g
/
m
2
)
 
+
 
C
e
t
u
x
i
m
a
b
 
Q
w
k
 
(
d
o
s
e
 
n
o
t
 
s
p
e
c
i
fi
e
d
)
C
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
 
p
r
e
l
i
m
i
n
a
r
y
 
a
n
a
l
y
s
i
s
:
 
R
e
s
p
o
n
s
e
 
(
c
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
,
 
t
u
m
o
r
 
m
a
r
k
e
r
 
d
e
c
r
,
 
d
e
c
r
 
i
n
 
m
e
t
 
s
i
z
e
)
 
n
o
t
e
d
 
i
n
 
9
/
1
1
 
p
t
s
 
(
1
 
p
t
 
n
o
n
-
e
v
a
l
)
.
 
3
 
p
t
s
 
d
e
v
e
l
 
b
r
a
i
n
 
m
e
t
s
 
d
u
r
i
n
g
 
T
x
.
 
9
 
p
t
s
 
h
a
d
 
p
r
i
o
r
 
t
a
x
a
n
e
 
T
x
.
S
o
m
e
 
i
m
p
r
e
s
s
i
v
e
 
c
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
s
 
 
n
o
t
e
d
 
e
v
e
n
 
i
n
 
t
a
x
a
n
e
 
p
r
e
-
t
r
e
a
t
e
d
 
p
t
s
.
 
T
o
x
i
c
i
t
y
 
i
s
 
c
u
m
u
l
a
t
e
d
 
e
x
p
e
c
t
e
d
 
t
o
x
i
c
i
t
y
 
 
o
f
 
e
a
c
h
 
o
f
 
t
h
e
 
a
g
e
n
t
s
.
1
6
9
p
h
a
s
e
 
i
i
 
 
e
r
l
o
t
i
n
i
b
 
 
D
i
c
k
l
e
r
 
M
N
.
 
 
B
r
e
a
s
t
 
C
a
n
c
e
r
 
 
R
e
s
 
T
r
e
a
t
.
 
2
0
0
9
;
 
 
1
1
5
:
1
1
5
–
2
1
.
4
7
p
t
s
 
w
/
l
o
c
a
l
l
y
 
a
d
v
a
n
c
e
d
 
o
r
 
M
B
C
 
w
/
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
 
d
u
r
i
n
g
 
o
r
 
a
f
t
e
r
 
t
h
e
r
a
p
y
 
w
i
t
h
 
a
n
 
a
n
t
h
r
a
c
y
c
l
i
n
e
,
 
t
a
x
a
n
e
,
 
a
n
d
 
c
a
p
e
c
i
t
a
b
i
n
e
 
(
c
o
h
o
r
t
 
1
)
,
 
o
r
 
d
u
r
i
n
g
 
o
r
 
a
f
t
e
r
 
t
h
e
r
a
p
y
 
w
i
t
h
 
o
n
e
 
c
h
e
m
o
-
t
h
e
r
a
p
y
 
r
e
g
i
m
e
n
 
(
c
o
h
o
r
t
 
2
)
E
r
l
o
t
i
n
i
b
 
1
5
0
 
m
g
 
p
O
 
q
d
a
y
R
e
s
p
o
n
s
e
 
r
a
t
e
S
a
f
e
t
y
,
 
t
i
m
e
 
t
o
 
p
r
o
-
g
r
e
s
s
i
o
n
,
 
s
u
r
v
i
v
a
l
O
n
e
 
p
t
 
i
n
 
e
a
c
h
 
c
o
h
o
r
t
 
h
a
d
 
p
R
.
E
r
l
o
t
i
n
i
b
 
h
a
d
 
m
i
n
i
m
a
l
 
a
c
t
i
v
i
t
y
 
i
n
 
 
u
n
s
e
l
e
c
t
e
d
 
p
r
e
v
i
o
u
s
l
y
 
t
r
e
a
t
e
d
 
w
o
m
e
n
 
 
w
i
t
h
 
a
d
v
a
n
c
e
d
 
B
C
1
7
2
(
C
o
n
t
i
n
u
e
d
)Minami et al
192  Breast Cancer: Basic and Clinical Research 2011:5
T
a
b
l
e
 
1
.
 
(
C
o
n
t
i
n
u
e
d
)
T
r
i
a
l
T
o
t
a
l
 
p
a
t
i
e
n
t
s
p
t
 
p
o
p
u
l
R
e
g
i
m
e
n
p
r
i
m
a
r
y
 
e
n
d
p
o
i
n
t
s
e
c
o
n
d
a
r
y
 
 
e
n
d
p
o
i
n
t
R
e
s
u
l
t
s
c
o
n
c
l
u
s
i
o
n
s
R
e
f
e
r
e
n
c
e
T
Y
R
O
s
I
n
e
 
K
I
n
A
s
e
 
i
n
h
i
b
i
t
o
r
s
p
h
a
s
e
 
i
i
 
 
s
u
n
i
t
i
n
i
b
 
 
B
u
r
s
t
e
i
n
 
H
J
.
 
 
J
 
C
l
i
n
 
O
n
c
o
l
.
 
 
2
0
0
8
;
2
6
:
 
 
1
8
1
0
–
1
6
.
6
4
M
B
C
 
p
t
s
 
p
r
e
v
i
o
u
s
l
y
 
t
r
e
a
t
e
d
 
w
i
t
h
 
 
a
n
t
h
r
a
c
y
c
l
i
n
e
 
 
a
n
d
 
t
a
x
a
n
e
s
u
n
i
t
i
n
i
b
 
5
0
 
m
g
/
d
 
i
n
 
6
 
w
e
e
k
s
 
c
y
c
l
e
s
 
 
(
4
 
w
k
s
 
o
n
,
 
2
 
w
k
s
 
o
f
f
)
O
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
r
a
t
e
 
7
 
p
t
s
 
a
c
h
i
e
v
e
d
 
P
R
 
(
3
 
h
a
d
 
T
N
B
C
)
.
 
O
R
R
 
=
 
1
1
%
.
 
5
%
 
h
a
d
 
s
t
a
b
l
e
 
d
i
s
e
a
s
e
 
.
6
 
m
o
n
t
h
s
.
 
M
e
d
i
a
n
 
t
i
m
e
 
t
o
 
p
r
o
g
r
e
s
s
i
o
n
 
w
a
s
 
1
0
 
w
k
s
,
 
o
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
 
w
a
s
 
3
8
 
w
k
s
S
u
n
i
t
i
n
i
b
 
i
s
 
a
c
t
i
v
e
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
 
h
e
a
v
i
l
y
 
p
r
e
t
r
e
a
t
e
d
 
M
B
C
.
1
7
8
p
h
a
s
e
 
i
 
 
s
u
n
i
t
i
n
i
b
 
 
B
e
r
g
h
 
J
.
 
J
 
 
C
l
i
n
 
O
n
c
o
l
.
 
 
2
0
1
0
;
2
8
:
 
 
a
b
s
t
r
a
c
t
 
 
L
B
A
1
0
1
0
.
5
3
3
N
e
w
l
y
 
d
x
 
H
E
R
2
-
 
 
m
e
t
a
s
t
a
t
i
c
 
o
r
 
 
a
d
v
a
n
c
e
d
 
B
C
A
r
m
 
1
:
 
d
o
c
e
t
a
x
e
l
 
 
7
5
 
m
g
/
m
2
,
 
d
a
y
 
1
,
 
 
s
u
n
i
t
i
n
i
b
 
3
7
.
5
 
m
g
/
d
a
y
 
p
O
,
 
d
a
y
 
2
–
1
5
,
 
q
3
w
e
e
k
s
.
 
A
r
m
 
2
:
 
 
d
o
c
e
t
a
x
e
l
 
1
0
0
 
m
g
/
m
2
 
q
3
w
e
e
k
s
p
F
S
O
R
R
,
 
O
S
,
 
s
a
f
e
t
y
p
r
o
l
o
n
g
e
d
 
p
F
S
 
a
n
d
 
p
r
o
l
o
n
g
e
d
 
O
S
 
w
a
s
 
n
o
t
 
a
c
h
i
e
v
e
d
.
S
u
n
i
t
i
n
i
b
 
a
n
d
 
d
o
c
e
t
a
x
e
l
 
i
s
 
n
o
t
 
a
 
 
r
e
c
o
m
m
e
n
d
e
d
 
t
r
e
a
t
m
e
n
t
 
o
p
t
i
o
n
 
f
o
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
n
e
w
l
y
 
d
i
a
g
n
o
s
e
d
 
 
a
d
v
a
n
c
e
d
 
B
C
.
1
7
9
m
T
O
R
 
i
n
h
i
b
i
t
o
r
s
 
p
h
a
s
e
 
i
i
 
 
e
v
e
r
o
l
i
m
u
s
 
 
E
l
l
a
r
d
 
S
L
.
 
J
 
 
C
l
i
n
 
O
n
c
o
l
.
 
2
0
0
9
;
 
2
7
:
 
4
5
3
6
–
4
1
.
4
9
p
a
t
i
e
n
t
s
 
#
 
1
 
 
t
r
e
a
t
m
e
n
t
 
f
o
r
 
M
B
C
E
v
e
r
o
l
i
m
u
s
 
1
0
 
m
g
 
q
d
a
y
 
v
e
r
s
u
s
 
7
0
 
m
g
 
q
w
e
e
k
l
y
O
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
 
o
r
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patients.  One  phase  II  trial  given  to  patients  with 
metastatic disease who had previously been treated 
with an anthracycline and taxane, found an overall 
response rate (ORR) of 15% in the TNBC subset.182 
But,  like  bevacizumab,  this  drug  is  increasingly 
thought to be ineffective in breast cancer.183,184 This 
lack of efficacy may be due to drug’s short half-life 
and the fact that optimal biologic and therapeutic dos-
ing has yet to be defined. Judicious patient selection 
may also play a key role in maximizing the efficacy 
of these anti-angiogenic agents.
Other targeted therapies
mTOR inhibitors
Preclinical studies demonstrate that mTOR inhibitors 
used alone are cytostatic in most tumor types and 
may clinically stabilize disease.185 Data from clinical 
studies  looking  at  single-agent  everolimus  have 
not  been  impressive. A  phase  II  study  comparing 
daily  dosing  with  weekly  dosing  of  single-agent 
everolimus in patients with recurrent/metastatic breast 
cancer found a low response rate, with no biologic 
correlates of response despite trends favoring benefit 
in  ER-positive  and  HER-2  negative  breast  cancer. 
However  the  fairly  modest  drug-related  toxicities 
encourage drug-combination studies.117,186 Two trials 
are currently investigating the use of everolimus in 
the treatment of TNBC (NCT01272141 is looking at 
the combination of lapatinib and everolimus in locally 
advanced or metastatic TNBC, and NCT00827567 
is examining the use of single agent everolimus in 
metastatic TNBC). As with all other targeted therapy, 
markers  of  mTOR  treatment  response  will  prove 
paramount in patient selection. Patients with cancer 
showing decreased PTEN, activated PI3K activation, 
or high p-mTOR have been reported to benefit the 
most from this class of drugs187–190 but work in this 
area must progress.
iGF-1R
Multiple phase I studies have found multiple human-
ized  mAbs  and  TKIs  to  be  safe  and  tolerable  in 
patients with solid tumors.191–194 Data from a tissue 
study  by  Witkiewicz  and  colleagues  demonstrated 
that IGF-1R is overexpressed and amplified in 29% 
of their TNBC samples.195 High IGF-1R expression 
was  significantly  correlated  with  negative  lymph 
nodes and, in patients younger than 55 years of age, Minami et al
194  Breast Cancer: Basic and Clinical Research 2011:5
with  longer  survival.  The  IGF-1R/insulin  receptor 
tyrosine kinase domain inhibitor BMS-754807 has 
demonstrated activity in TNBC123 and ongoing trials 
are evaluating the efficacy of this class of targeted 
treatment in breast cancer.
Androgen receptor inhibition
NCT00468715  is  an  ongoing  study  evaluating  the 
use of bicalutamide, an anti-androgen agent used for 
treatment of prostate cancer in the treatment of HR-
negative, AR-positive breast cancer. Bicalutamide has 
been well-tolerated in this population and preliminary 
analysis  has  demonstrated  disease  stabilization  in 
ER/PR negative, AR positive with AR inhibition.196
Heat shock protein (Hsp) 90 inhibitor
Clinical  studies  are  evaluating  Hsp  90  inhibitor 
AUY922  and  IPI-504,  but  only  in  ER  and  HER2 
positive disease (NCT0181613 and NCT01081600). 
Whether agents of this class will prove effective in 
vivo and in TNBC specifically, remains to be seen.
conclusion
The tumor biology of TNBC, basal-like breast   cancer, 
BRCA-mutated machinery, and claudin-low disease 
is  both  specific  and  diverse.  While  conventional 
  chemotherapeutic  regimens  can  be  successful  in 
treating women with TNBC and basal-like disease, 
it  is  clear  that  this  pool  of  diseases  is  heteroge-
neous in nature and must be further sub-categorized. 
Emerging therapies aimed at damaging DNA, angio-
genic  players,  tubulin  structures,  mTOR,  IGF-1R, 
AR, and HSP 90 show promise in early stage studies, 
but their clinical performance has yet to be defini-
tively proven. No doubt much of the work to come 
must focus on generating more specific terminology 
in order to identify the optimal patient population for 
each treatment.
Disclosure
This  manuscript  has  been  read  and  approved  by 
all authors. This paper is unique and is not under 
  consideration by any other publication and has not 
been  published  elsewhere.  The  authors  and  peer 
reviewers of this paper report no conflicts of   interest. 
The  authors  confirm  that  they  have  permission  to 
reproduce any copyrighted material.
References
  1.  Smith I, Procter M, Gelber R, et al. Two-year follow-up of trastuzumab 
after adjuvant chemotherapy in HER2-positive breast cancer: a randomized 
controlled trial. Lancet. 2007;369:29–36.
  2.  Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after 
adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 
2005;353:1659–72.
  3.  Cobleigh M, Vogel C, Tripathy D, et al. Multinational study of the effi-
cacy and safety of humanized anti-HER2 monoclonal antibody in women 
who  have  HER2-overexpressing  metastatic  breast  cancer  that  has  pro-
gressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17: 
2639–48.
  4.  Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing 
doxorubicin and cyclophosphamide followed by docetaxel (ACT) with 
doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab 
(ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 
positive early breast cancer patients: BCIRG 06 study[abstract 1]. Breast 
Cancer Rest Treat. 2005;94 Suppl 1. Data presented at the San Antonio 
Breast Cancer Symposium.
  5.  Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemo-
therapy for operable HER2-positive breast cancer: combined analysis of 
NSABP B-31 and NCCTG N9831. N Engl J Med. 2005;353:1673–84.
  6.  Korsching  E,  Jeffrey  SS,  Meinerz  W,  et  al.  Basal  carcinoma  of  the 
breast  revisited:  an  old  entity  with  new  interpretations.  J  Clin  Pathol. 
2008;61:553–60.
  7.  Haffty BG, Yang Q, Reiss M. Locoregional relapse and distant metastasis 
in conservatively managed triple negative early-stage breast cancer. J Clin 
Oncol. 2006;24:5652–7.
  8.  Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes and 
survival in the Carolina breast cancer study. JAMA. 2006;295:2492–502.
  9.  Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I. Prognostic 
markers in triple-negative breast cancer. Cancer. 2007;109:25–32.
  10.  Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen 
receptor  (ER)-negative,  progesterone  receptor(PR)-negative,  and  HER2-
negative invasive breast cancer, the so-called triple-negative phenotype. 
Cancer. 2007;109:1721–8.
  11.  Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic 
options. Lancet. 2007;8:235–44.
  12.  Stockmans G, Deraedt K, Wildiers H, et al. Triple-negative breast cancer. 
Curr Opin Oncol. 2008;20:614–20.
  13.  Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast 
tumors. Nature. 2000;406:747–52.
  14.  Foulkes W, Smith I, Reis-Filho J. Triple-Negative Breast Cancer. N Engl J 
Med. 2010;363:1938–48.
  15.  Rakha  EA,  Reis-Filho  JS,  Ellis  IO.  Basal-like  breast  cancer:  a  critical 
review. J Clin Oncol. 2008;26:2568–81.
  16.  Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical 
characterization of the basal-like subtype of invasive breast carcinoma. Clin 
Cancer Res. 2004;10:5367–74.
  17.  Birnbaum D, Bertucci F, Ginestier C, et al. Basal and luminal breast cancers: 
basic or luminous? Int J Oncol. 2004;25:249–58.
  18.  Calza  S,  Hall  P, Auer  G,  et  al.  Intrinsic  molecular  signature  of  breast 
cancer in a population-based cohort of 412 patients. Breast Cancer Res. 
2006;8:R34.
  19.  Fulford LG, Easton DF, Sofronis A, et al. Specific morphological features 
predictive for the basal phenotype in grade 3 invasive ductal carcinomas of 
the breast. Pathol Int. 2004;54:A2–3.
  20.  Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: 
true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005;18: 
1321–8.
  21.  Matos I, Dufloth R, Alvarenga M, et al. p53, cytokeratin 5, and P-cadherin: 
three molecular markers to distinguish basal phenotype in breast carcinomas. 
Virchows Arch. 2005;447:688–94.
  22.  Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and 
prognosis based on gene expression profiles from a population-based study. 
Proc Natl Acad Sci USA. 2003;100:10393–8.Management options in TNBC
Breast Cancer: Basic and Clinical Research 2011:5  195
  23.  Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling 
and histopathological characterization of triple-negative/basal-like breast 
carcinomas. Breast Cancer Res. 2007;9:R65.
  24.  Jacquemeier  J,  Padovani  L,  Rabayrol  L,  et  al.  Typical  medullary  breast 
carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207:260–8.
  25.  Dent R, Trudeau M, Pritchard K, et al. Triple-negative breast cancer: clinical 
features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.
  26.  Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast 
cancers? Int J Cancer. 2008;123:236–40.
  27.  Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations 
in triple negative breast cancer (BC). J Clin Oncol (Meeting Abstracts). 
2006;24(18 Suppl):508.
  28.  Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-
like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71.
  29.  Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1status in 
patients with breast cancer using estrogen receptor and basal phenotype. 
Clin Cancer Res. 2005;11:5175–80.
  30.  Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations 
and  a  basal  epithelial  phenotype  in  breast  cancer.  J  Natl  Cancer  Inst. 
2003;95:1482–5.
  31.  Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor 
subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 
2003;100:8418–23.
  32.  Turner  N,  Tutt A, Ashworth A.  Hallmarks  of  ‘BRCAness’  in  sporadic 
cancers. Nat Rev Cancer. 2004;4:814–9.
  33.  Turner  NC,  Reis-Filho  JS,  Russell  AM,  et  al.  BRCA1  dysfunction  in 
sporadic basal-like breast cancer. Oncogene. 2007;14:2126–32.
  34.  Adelaide J, Finetti P, Bekhouche I, et al. Integrated profiling of basal and 
luminal breast cancers. Cancer Res. 2007;67:11565–75.
  35.  Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast 
carcinomas distinguish tumor subclasses with clinical implications. Proc 
Natl Acad Sci USA. 2001;9819:10869–74.
  36.  Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is 
an independent prognostic marker for poor outcome in both node-negative 
and node-positive breast cancer. Acta Oncologica. 2000;39:327–33.
  37.  Reis-Filho  JS,  Tutt  AJ.  Triple  negative  tumours:  a  critical  review. 
Histopathology. 2008;52:108–18.
  38.  Young S, Pilarski R, Donenburg T, et al. The prevalence of BRCA mutations 
among  young  women  with  triple-negative  breast  cancer.  BMC  Cancer. 
2009;9:86.
  39.  Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria 
for  BRCA  mutation  testing  in  breast  cancer  survivors.  J  Clin  Oncol. 
2010;28:4214–20.
  40.  Herschkowitz J, Simin K, Weigman V, et al. Identification of conserved 
gene expression features between murine mammary carcinoma models and 
human breast tumors. Genome Biol. 2007;8:R76.
  41.  Prat A, Parker J, Karginova O, et al. Phenotypic and molecular characteriza-
tion of the claudin-low intrinsic subtype of breast cancer. Breast Cancer 
Res. 2010;12:R68.
  42.  Creighton  CJ,  Li  X,  Landis  M,  et  al.  Residual  breast  cancers  after 
conventional  therapy  display  mesenchymal  as  well  as  tumor-initiating 
features. Proc Natl Acad Sci USA. 2009;106:13820–925.
  43.  Perou  CM.  Molecular  stratification  of  triple-negative  breast  cancers. 
Oncologist. 2011;16:61–70.
  44.  Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. 
2011;5:5–23.
  45.  Perou CM, Borresen-Dale AL. Systems biology and genomics of breast 
cancer. Cold Spring Harb Persepct Biol. 2011;3.
  46.  Morris  G,  Naidu  S,  Topham  K,  et  al.  Differences  in  breast  carcinoma 
characteristics in newly diagnosed African-American and Caucasian patients: 
a single-institution compilation compared with the National Cancer Insti-
tute’s Surveillance, Epidemiology, and end results database. Cancer. 2007; 
110:876–84.
  47.  Freedman G,  Anderson P, Li T, et al. Locoregional recurrence of triple-negative 
breast cancer after breast-conserving surgery and radiation. Cancer. 2009; 
115:946–51.
  48.  Millikan R, Newman B, Tse CK, et al. Epidemiology of basal-like breast 
cancer. Breast Cancer Res Treat. 2008;109:123–39.
  49.  Lund M, Butler E, Hair B, et al. Age/race differences in HER2 testing and 
in incidence rates for breast cancer triple subtypes: a population-based study 
and first report. Cancer. 2010;116:2549–59.
  50.  Lund M, Butler E, Bumpers H, et al. High prevalence of triple-negative 
tumors in an urban cancer center. Cancer. 2008;113:608–15.
  51.  Tischkowitz M, Brunet J, Bégin LR, et al. Use of immunohistochemical 
markers can refine prognosis in triple negative breast cancer. BMC Cancer. 
2007;7:134.
  52.  Phipps A, Malone K, Porter P, et al. Reproductive and hormonal risk factors 
for  postmenopausal  luminal,  Her-2-overexpressing,  and  triple-negative 
breast cancer. Cancer. 2008;113:1521–6.
  53.  Yang X, Sherman M, Rimm D et al. Differences in risk factors for breast 
cancer molecular subtypes in a population-based study. Cancer Epidemiol 
Biomarkers Prev. 2007;16:439–43.
  54.  Trivers K, Lund M, Porter P, et al. The epidemiology of triple-negative 
breast cancer, including race. Cancer Causes Control. 2009;20:1071–82.
  55.  Yang  XR,  Pfeiffer  RM,  Garcia-Cloases  M,  et  al.  Hormonal  markers  in 
breast cancer: coexpression, relationship with pathologic characteristics, and 
risk factor associations in a population-based study. Cancer Res. 2007;67: 
10608–17.
  56.  Kwan M, Kushi L, Weltzien E, et al. Epidemiology of breast cancer subtypes 
in two prospective cohort studies of breast cancer survivors. Breast Cancer 
Res. 2009;11:R31.
  57.  Slattery M, Sweeney C, Edwards S, et al. Body size, weight change, fat 
distribution  and  breast  cancer  risk  in  Hispanic  and  non-Hispanic  white 
women. Breast Cancer Rest Treat. 2007;102:85–101.
  58.  Maiti B, Kundranda MN, Jin T, et al. The association of metabolic syndrome 
with triple-negative breast cancer. J Clin Oncol. 2009;27:479–83.
  59.  Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: 
clinical significance. Am J Surg. 2006;191:657–64.
  60.  Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typically 
medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, 
a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24.
  61.  Rakha E, Ellis I. Triple-negative/basal-like breast cancer: review. Pathology. 
2009;41:40–7.
  62.  Bhargava R, Geral WL, Li AR, et al. EGFR gene amplification in breast 
cancer: correlation with epidermal growth factor receptor mRNA and protein 
expression and HER-2 status and absence of EGFR-activating mutations. 
Mod Pathol. 2005:18:1027–33.
  63.  Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early 
breast cancer. J Clin Oncol. 2005;23:7212–20.
  64.  Fulford G, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal 
carcinoma  of  the  breast:  patterns  of  metastasis  and  long-term  survival. 
Breast Cancer Res. 2007;9:R4.
  65.  van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 
17 and 5 identifies a group of breast carcinomas with poor clinical outcome. 
Am J Pathol. 2002;161:1991–6.
  66.  Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined 
by  five  biomarkers  has  superior  prognostic  value  than  triple-negative 
phenotype. Clin Cancer Res. 2008;14:1368–76.
  67.  Rakha E, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast 
cancer: distinguishing between basal and non-basal subtypes. Clin Cancer 
Res. 2009;15:2302–10.
  68.  Liu  H,  Fan  Q,  Zhang  Z,  Xiao  L,  Huiping  Y,  Meng  F.  Basal-HER2 
phenotype shows poorer survival than basal-like phenotype in hormone 
receptor-negative invasive breast cancers. Hum Pathol. 2008;39:167–74.
  69.  Choi YL, Oh E, Park S, et al. Triple-negative, basal-like, and quintuple-
negative breast cancers: better prediction model for survival. BMC Cancer. 
2010;10:507.
  70.  Banerjee S, Reis-Filho J, Ashley S, et al. Basal-like breast carcinomas: clinical 
outcome and response to chemotherapy. J Clin Pathol. 2006;59:729–35.
  71.  Rodriguez-Pinilla S, Sarrio D, Honrado E, et al. Prognostic significance of 
basal-like phenotype and fascin expression in node-negative invasive breast 
carcinomas. Clin Cancer Res. 2006;12:1533–9.Minami et al
196  Breast Cancer: Basic and Clinical Research 2011:5
  72.  Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implications 
of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-
proliferation +) phenotype of BRCA1-related breast cancer. J Natl Cancer 
Inst. 2003;95:1482–5.
  73.  Luck AA, Evans AJ, Green AR, et al. The influence of basal phenotype on 
the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol). 2008;20: 
40–5.
  74.  Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer 
metastasis to lung. Nature. 2005;436:518–24.
  75.  Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and 
their prognosis. South Med J. 1988;81:1109–2.
  76.  Osborne  CR,  Kanna  L,  Ashfaq  R,  et  al.  Clinical  and  pathological 
characterization  of  basal-like  breast  cancer.  Breast  Cancer  Res  Treat.   
2005;94:abstract 2098.
  77.  Foulkes WD, Metcalfe K, Hanna W, et al. Disruption of the expected posi-
tive correlation between breast tumor size and lymph node status in BRCA-1 
related breast carcinoma. Cancer. 2003;98:1569–77.
  78.  Chang  HR,  Glaspy  J,  Elashoff  R,  Kass  F,  Allison  MD,  Chung  DU. 
Differential response of triple-negative breast cancer to a docetaxel and 
carboplatin-based neoadjuvant treatment. Cancer. 2010;116:4227–37.
  79.  Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to 
radiate? Ann Surg Oncol. 2011;18:94–103.
  80.  Voduc KD, Cheang MC, Tyldesely S, Gelmon K, Nielsen TO, Kennecke 
H. Breast cancer subtypes and the risk of local and regional relapse. J Clin 
Oncol. 2010;28:1684–91.
  81.  Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated 
by estrogen receptor, progesterone receptor, and HER-2 is associated with 
local and distant recurrence after breast-conserving therapy. J Clin Oncol. 
2008;26:2373–8.
 82.  Wilkinson  JB,  Reed  RE,  Wallace  MF,  et  al.  Outcomes  of   breast  cancer 
patients with triple negative receptor status treated with accelerated partial 
breast irradiation. Int J Radiat Oncol Biol Phys. 2011 Feb 22;[Epub ahead of 
print].
  83.  Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates 
in  young  women  with  BRCA-positive  breast  cancers  after  neoadjuvant 
chemotherapy. J Clin Oncol. 2010;28:375–9.
  84.  Silver  DP,  Richardson AL,  Eklund AC,  et  al.  Efficacy  of  neoadjuvant 
cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;29:1145–53.
  85.  Isakoff  SJ. Triple-negative  breast  cancer:  role  of  specific  chemotherapy 
agents. Cancer J. 2010;16:53–61.
  86.  Kriege M, Seynaeve C, Mijers-Haljboer H, et al. Sensitivity to first-time 
chemotherapy for metastatic breast cancer in BRCA 1 and BRCA 2 mutation 
carriers. J Clin Oncol. 2009;27:3764–71.
  87.  Santana-Davila R, Perez EA. Treatment options for patients with triple-
negative breast cancer. J Hematol Oncol. 2010;3:42.
  88.  Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone 
analog with a mode of action similar to paclitaxel but possessing superior 
antitumor efficacy. Clin Cancer Res. 2001;7:1427–37.
  89.  Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study 
of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol. 
2009;27:526–34.
  90.  Cortez J, Baselga J. Targeting the microtubules in breast cancer beyond 
taxanes: the epothilones. Oncologist. 2007;12:271–81.
  91.  Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on 
alpha, beta-tubulin by electron crystallography. Science. 2004;305:866–9.
  92.  Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat 
Res Cancer. 2010;10:194–204.
  93.  Horak CE, Lee FY, Xu L, Galbraith S, Baselga J. High beta-III tubulin 
expression  in  triple-negative  (TN)  breast  cancer  (BC)  subtype  and 
correction to ixabepilone response: a retrospective analysis. J Clin Oncol. 
2009;27:abstract 3587.
  94.  Cortes  J,  O’Shaughnessy  J,  Loesch  D,  et  al.  Eribulin  monotherapy 
versus treatment of physician’s choice in patients with metastatic breast 
cancer  (EMBRACE):  a  phase  3  open-label  randomized  study.  Lancet. 
2011;377:914–23.
  95.  Rugo HS, Thomas ES, Lee RK, Fein LE, Peck R, Verrill M. Combination 
therapy with the novel epothilone B analog, ixabepilone, plus capecitabine 
has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracy-
clines and taxanesPResented at the 30th Annual San Antonio Breast Can-
cer Symposium, San Antonio, TX, December 16, 2008; abstract 6069.
  96.  Anders CK, Winer EP, Ford JM, et al. Poly(ADP-ribose) polymerase inhi-
bition: “Targeted” therapy for triple-negative breast cancer. Clin Cancer 
Res. 2010;16:4702–10.
  97.  Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-
ribose) polymerase in oncology. Clin Cancer Res. 2007;13:1383–8.
  98.  Martin-Oliva  D,  Aguilar-Quesada  R,  O’Valle  F,  et  al.  Inhibition  of 
poly(ADP-ribose) polymerase modulates tumor-related gene expression, 
including hypoxia-inducible factor-1 activation, during skin carcinogen-
esis. Cancer Res. 2006;66:5744–56.
  99.  Vaupel  P.  The  role  of  hypoxia-induced  factors  in  tumor  progression. 
Oncologist. 2004;9 Suppl 5:10–7.
  100.  Greenberg  S,  Rugo  HS.  Triple-negative  breast  cancer:  role  for 
antiangiogenic agents. Cancer Journal. 2010;16:33–8.
  101.  Marty  M,  Pivot  X.  The  potential  of  anti-vascular  endothelial  growth 
factor  therapy  in  metastatic  breast  cancer:  clinical  experience  with 
anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008;44: 
912–20.
  102.  Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus 
paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 
2666–76.
  103.  Tan  DS,  Marchio  C,  Jones  RL,  et  al.  Triple-negative  breast  cancer: 
molecular  profiling  and  prognostic  impact  in  adjuvant  anthrocycline-
treated patients. Breast Cancer Res Treat. 2007;111:27–44.
  104.  Bian J. Suppression of in vivo tumor growth and induction of suspension cell 
death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis. 
1996;17:1805–11.
  105.  Finn  RS,  Derin  J,  Ginther  C,  et  al.  Dasatinib,  an  orally  active  small 
molecule inhibitor of both the src and abl kinases, selective inhibitors 
growth of basal-type/”triple-negative” breast cancer cell lines growing in 
vitro. Breast Cancer Res Treat. 2007;105:319–26.
  106.  Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling 
network for cancer therapy. J Clin Oncol. 2009;27:2278–81.
  107.  Wullschleger  S,  Loewith  R,  Hall  MN.  TOR  signaling  in  growth  and 
metabolism. Cell. 2006;124:471–84.
  108.  De Benedetti A, Graff JR. EIF-4E expression and its role in malignancies 
and metastases. Oncogene. 2004;23:3189–99.
  109.  Jastrzebski K, Hannan KM, Tchoubrieva EB, et al. Coordinate regula-
tion of ribosome biogenesis and function by the ribosomal protein S6 
kinase,  a  key  mediator  of  mTOR  function.  Growth  Factors.  2007;25: 
209–26.
  110.  Nakamura  JL,  Garcia  E,  Pieper  RO.  S6  K1  plays  a  key  role  in  glial 
transformation. Cancer Res. 2008;68:6515–23.
 111.  Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR 
complex integrity and regulates Akt phosphorylation and substrate speci-
ficity. Cell. 2006;127:125–37.
  112.  Yang Q, Inoki K, Ikenoue T, et al. Identification of SIN1 as an essential 
TORC2 component required for complex formation and kinase activity. 
Genes Dev. 2006;20:2820–32.
  113.  Pearce  LR,  Huang  X,  Boudreau  J,  et  al.  Identification  of  protor  as  a 
novel  Rictor-finding  component  of  mTOR  complex-2.  Biochem  J. 
2007;405:513–22.
  114.  Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/PKB 
phosphorylation and its isoforms define three distinct mTORC2 s. Curr 
Biol. 2006:1865–70.
  115.  Martin J, Maseri J, Berath A, et al. Hsp70 associates with Rictor and is 
required  for  mTORC2  formation  and  activity.  Biochem  Biophys  Res 
Commun. 2008;372:578–83.
  116.  Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding protein of 
mTOR, defines a rapamycin-insensitive and raptor-independent pathway 
that regulates the cytoskeleton. Curr Biol. 2004;14:1296–302.Management options in TNBC
Breast Cancer: Basic and Clinical Research 2011:5  197
  117.  Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study 
comparing  two  schedules  of  everolimus  in  patients  with  recurrent/
metastatic breast cancer: NCIC clinical trials group IND.163. J Clin Oncol. 
2009;27:4536–41.
  118.  Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in 
cancer growth and metastasis: overview and recent insights. Endocr Rev. 
2007;28:20–47.
  119.  Kline J, Chervoneva I, Freydin B, et al. Insulin-like growth factor receptor 
(IGF1R) is overexpressed in a subset of triple negative breast cancers. 
2010; presented at American Association for Cancer Research International 
Conference on Molecular Diagnostics in Cancer Therapeutic Develop-
ment: Abstract A29.
  120.  Lerma E, Peiro G,  Ramon T, et al. Immunohistochemical heterogene-
ity  of  breast  carcinomas  negative  for  estrogen  receptors,  progesterone 
receptors  and  Her2/neu  (basal-like  breast  carcinomas).  Mod  Pathol. 
2007;20:1200–7.
  121.  Myers  MG,  Grammer  TC,  Wang  LM,  et  al.  Insulin  receptor  sub-
strate-1  mediates  phosphatidylinositol  3’-kinase  and  p70S6k  signaling 
during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. 
J Biol Chem. 1994;269:28783–9.
  122.  Heskamp  S,  Hannek  WM,  van  Laarhoven,  et  al.  ImmunoSPECT  and 
ImmunoPET of IGF-1R expression with the radiolabeled antibody R1507 in 
a triple-negative breast cancer model. J Nucl Med. 2010;51:1565–72.
  123.  Litzenburger BC, Creighton CJ, Tsimelzon A, et al. High-IGF-1R activity 
in triple-negative breast cancer cell lines and tumorgrafts correlate with 
sensitivity to anti-IGF-1R therapy. Clin Cancer Res. 2010; epub ahead of 
print.
  124.  Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen 
receptor. Cancer J. 2010;16:62–5.
  125.  Doane AS, Damso M, Lal P, et al. An estrogen receptor negative breast 
cancer  subset  characterized  by  a  hormonally  regulated  transcriptional 
program and response to androgen. Oncogene. 2006;25:3994–4008.
  126.  Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary 
breast cancer. Ann Oncol. 2010;21:488–92.
  127.  Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen 
receptor in breast cancer: expression of estrogen receptor-positive tumors 
and in estrogen receptor-negative tumor with apocrine differentiation. Mod 
Pathol. 2010;23:205–12.
  128.  Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor 
levels and association with PIK3CA mutations and prognosis in breast 
cancer. Clin Cancer Res. 2009;15:2472–8.
  129.  Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp 90 inhibitor PU-H71, a 
multimodal inhibitor of malignancy, induces complete responses in triple-
negative breast cancer model. Proc Natl Acad Sci USA. 2009;106:8368–73.
  130.  Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy 
and long-term survival in patients with triple-negative breast cancer. J Clin 
Oncol. 2008;26:1275–81.
  131.  Rastogi  R, Anderson  SJ,  Bear  HD,  et  al.  Preoperative  chemotherapy: 
updates of National Surgical Adjuvant Breast and Bowel Project protocols 
B-18 and B-27. J Clin Oncol. 2008;26:778–85.
  132.  Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary 
tumor  chemosensitivity  of  breast  cancer  subtypes.  Clin  Cancer  Res. 
2007;13:2329–34.
  133.  Mauri  D,  Pavlidis  N,  Ioannidis  JP.  Neoadjuvant  versus  adjuvant 
systemic treatment in breast cancer: a meta-analysis. J Nat Cancer Ins. 
2005;97:188–94.
  134.  Mehta  RS.  Dose-dense  and/or  metronomic  schedules  of  specific 
chemotherapies consolidate the chemosensitivity of triple-negative breast 
cancer: a step toward reversing triple-negative paradox. J Clin Oncol. 
2008;26:3286–7.
  135.  Green  MC,  Buzdar  AU,  Smith  T,  et  al.  Weekly  paclitaxel  improves 
pathologic complete remission in operable breast cancer when compared 
with once-every-3-weeks paclitaxel. J Clin Oncol. 2005;23:5983–92.
  136.  Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant 
treatment of breast cancer. N Engl J Med. 2008;358:1663–71.
  137.  Von  Minckwitz  G,  Untch  M,  Nuesch  E,  et  al.  Impact  of  treatment 
characteristics on response of different breast cancer phenotypes: pooled 
analysis of the German neo-adjuvant chemotherapy trial. Breast Cancer 
Res Treat. 2011;125:145–56.
  138.  Gluz  O,  Nitz  UA,  Harbeck  N,  et  al.  Triple-negative  high-risk  breast 
cancer  derives  particular  benefit  from  dose  intensification  of  adju-
vant chemotherapy: results of WSG AM-01 trial. Ann Oncol. 2008;19: 
861–70.
  139.  Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete 
responses  in  aggressive  stage  II  to  III  breast  cancers  with  every-4-
week-carboplatin  and  weekly  paclitaxel  with  or  without  trastuzumab: 
a  Brown  University  Oncology  Group  study.  J  Clin  Oncol.  2008;927: 
4693–700.
  140.  Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment 
of  locally  advanced  triple  negative  (hormone  receptor  negative  and 
HER2 negative) breast cancer with epirubicin, cisplatin, and infusional 
fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol. 
2008;62:667–72.
  141.  Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-
positive breast cancer. N Engl J Med. 2005;352:2302–13.
  142.  Hugh J, Hanson J, Chon M, et al. Breast cancer subtypes and response 
to docetaxel in node-positive breast cancer: use of immunohistochemical 
definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168–76.
  143.  Early Breast Cancer Trialists’ Collaborate Group. Effects of chemotherapy 
and hormonal therapy for early breast cancer on recurrence and 15-year 
survival:  an  overview  of  the  randomized  trials.  Lancet.  2005;365: 
1687–717.
  144.  Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role 
of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 
2004;96:1659–68.
  145.  Rodriguez AA, Markis A, Wu MF, et al. DNA repair signature is associated 
with anthracycline response in triple negative breast cancer patients. Breast 
Cancer Res Treat. 2010;123:189–96.
  146.  Colleoni  M,  Cole  B,  Viale  GV,  et  al.  Classical  cyclophosphamide, 
methotrexate, and fluorouracil chemotherapy is more effective in triple-
negative, node-negative breast cancer: results from two randomized trials 
of  adjuvant  chemoendocrine  therapy  for  node-negative  breast  cancer. 
J Clin Oncol. 2010;28:2966–73.
  147.  Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of 
locally advanced triple negative (hormone receptor negative and HER2 
negative) breast cancer with epirubicin, cisplatin and infusional fluorouracil 
followed by weekly paclitaxel. Cancer Chemotherapy Pharmacol. 2008;62: 
667–72.
  148.  Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatin-
epirubicin-paclitaxel with G-CSF support in triple-negative large operable 
breast cancer. Ann Oncol. 2009;201:1185–92.
  149.  Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevaci-
zumab in triple-negative breast cancer (TNBC): safety and efficacy. J Clin 
Oncol. 2009;27:abstract 551.
  150.  Mazouni C, Kau SW, Frye D, et al. Inclusion of taxanes, particularly 
weekly  paclitaxel,  in  preoperative  chemotherapy  improves  pathologic 
complete response in estrogen receptor-positive breast cancers. Ann Oncol. 
2007;18:874–80.
  151.  Rouzier  R,  Perou  CM,  Symmans  WF,  et  al.  Breast  cancer  molecular 
subtypes respond differently to preoperative chemotherapy. Clin Cancer 
Res. 2005;11:5678–85.
  152.  Mamounas EP, Bryant J, Lembersky B, et al. Pacitaxel after doxorubicin 
plus  cyclophosphamide  as  adjuvant  chemotherapy  for  node-positive 
breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–96.
  153.  Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/
HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 
2010;121:261–71.
  154.  Bunnell C, Vahdat L, Schwartzberg L, et al. Phase I/II study of ixabepilone 
plus capecitabine in anthrocycline-pretreated/resistant and taxane-resistant 
metastatic breast cancer. Clin Breast Cancer. 2008;8:234–41.Minami et al
198  Breast Cancer: Basic and Clinical Research 2011:5
  155.  Thomas  ES,  Gomez  HL,  Li  RK,  et  al.  Ixabepilone  plus  capecitabine 
for metastatic breast cancer progressing after anthracycline and taxane 
treatment. J Clin Oncol. 2007;25:5210–7.
  156.  Rugo HS, Roche H, Thomas E, et al. Ixabepilone plus capecitabine vs. 
capecitabine  in  patients  with  triple  negative  tumors:  a  pooled  analy-
sis  of  patients  from  two  large  phase  III  clinical  studies.  Poster  pre-
sented  at  the  San Antonio  Breast  Cancer  Symposium.  Dec  12,  2008:   
poster 3057.
  157.  Ibrahim NK. Ixabepilone development across the breast cancer continuum: 
a paradigm shift. Cancer Manag Res. 2010;2:169–79.
  158.  Fong  PC,  Boss  DS,  Yap  TA,  et  al.  Inhibition  of  poly  (ADP-ribose) 
polymerase  in  tumors  from  BRCA  mutation  carriers.  N  Engl  J  Med. 
2009;361:123–34.
  159.  Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase 
inhibitor  olaparib  in  patients  with  BRCA1  or  BRCA2  mutations  and 
advanced  breast  cancer:  a  proof-of-concept  trial.  Lancet.  2010;376: 
235–44.
  160.  Gelmon K, Hirte H, Robidoux A, et al. Can we define tumors that response 
to PARP inhibitors? A phase II correlative study of olaparib in advanced 
serous ovarian cancer and triple negative breast cancer. J Clin Oncol. 
2010;28:abstract 3002.
  161.  Dent R, Lindeman G, Clemons M, et al. Safety and efficacy of the oral 
PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for 
the first- or second-line treatment of patients with netastatic triple-negative 
breast cancer: results from the safety cohort of a phase I/II multicenter 
trial. J Clin Oncol. 2010;28:1018.
  162.  Rouleau  M,  Patel A,  Hendzel  MJ,  Kaufmann  SH,  Poirier  GG.  PARP 
inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:429–301.
  163.  O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy 
in  metastatic  triple-negative  breast  cancer.  N  Engl  J  Med.  2011;364: 
205–14.
  164.  Kummar S, Chen AP, Ji JJ, et al. A phase I study of ABT-888 (A) in 
combination  with  metronomic  cyclophosphamide  (C)  in  adults  with 
refractory solid tumors and lymphomas. 2010;28: abstract 2605.
  165.  Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP 
inhibitor  veliparib  (ABT888)  and  temozolomide  for  metastatic  breast 
cancer. J Clin Oncol. 2010;28: abstract 1019.
  166.  Carey LA, Sharpless NE. PARP and cancer—if it’s broke, don’t fix it. 
N Engl J Med. 2011;364:277–9.
  167.  Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus 
docetaxel compared with placebo plus docetaxel for the first-line treatment 
of human epidermal growth factor receptor 2-negative metastatic breast 
cancer. J Clin Oncol. 2010;28:3238–47.
  168.  Robert NG, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-
blind, placebo-controlled, phase III trial of chemotherapy with or without 
bevacizumab  (B)  for  first-line  treatment  of  HER2-negative  locally 
recurrent  or  metastatic  breast  cancer  (MBC).  J  Clin  Oncol.  2009;27: 
abstract 1005.
  169.  Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab 
in cancer patients: a meta-analysis. JAMA. 2011;205:487–94.
  170.  Carey LA, Rugo HS, Marcom PK, et al. TBCRC001: EGFR inihibition 
with cetuximab in metastatic triple negative (basal-like) breast cancer. 
J Clin Oncol. 2008;26 Suppl 15:43S, abstract 1009.
  171.  Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cis-
platin increases overall response rate (ORR) and progression free sur-
vival (PFS) in metastatic triple-negative breast cancer (TNBC): results 
of a randomized phase II study (BALI-1). Ann Oncol. 2010;21(suppl8): 
abstract 2740.
  172.  O’Shaughnessy  J,  Weckstein  DJ,  Vukelja  SJ,  et  al.  Randomized 
phase II study of weekly irinotecan/carboplatin with or without cetux-
imab in patients with metastatic breast cancer. Br Cancer Res Treat. 2007; 
106 Suppl 1:S32, abstract 308.
  173.  Nechushtan H, Steinberg H, Peretz T. Preliminary results of a phase I/II 
of a combination of cetuximab and taxane for triple negative breast cancer 
patients. J Clin Oncol. 2009;27:abstract 12018.
  174.  Resch G, Schaberl-Moser R, Kier P, et al. Infusion reactions to the chimeric 
EGFR  inhibitor  cetuximab—change  to  the  fully  human  anti-EGFR 
monoclonal antibody panitumumab is safe. Ann Oncol. 2011;22:486–7.
  175.  Nicholson RI, Hutcheson IR, Knowlden JM, et al. Nonendocrine pathways 
and  endocrine  resistance:  observations  with  antiestrogens  and  signal 
transduction inhibitors in combination. Clin Can Res. 2004;10:346–54.
  176.  Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and 
safety of erlotinib in patients with locally advanced or metastatic breast 
cancer. Breast Cancer Res Treat. 2009;115:115–21.
  177.  Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview 
of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 
2005;12:S135–44.
  178.  Guix M, Granja NM, Meszoely I, et al. Short preoperative treatment with 
erlotinib  inhibits  tumor  cell  proliferation  in  hormone  receptor-positive 
breast cancer. J Clin Oncol. 2008;26:897–906.
  179.  Corkery B, Crown J, Clynes M, O’Donovan N. Epidermal growth factor 
receptor as a potential therapeutic target in triple-negative breast cancer. 
Ann Oncol. 2009;20:862–7.
  180.  Brower V. Search for new treatments intensifies for triple-negative breast 
cancer. J Natl Cancer Inst. 2009;101:1536–7.
  181.  Moulder S, Yan K, Huang F, et al. Development of candidate genomic 
markers to select breast cancer patients for dasatinib therapy. Mol Cancer 
Ther. 2010;9:1120–7.
  182.  Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, 
an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic 
breast cancer previously treatment with an anthracycline and taxane. J Clin 
Oncol. 2008:26:1810–6.
  183.  Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with 
docetaxel (D) versus D alone for the first-line treatment of advanced breast 
cancer (ABC). J Clin Oncol. 2010;28:abstract LBA1010.
  184.  Crown J, Dieras V, Staroslawska, et al. Phase III trial of sunitinib (SU) in 
combination with capecitabine © versus C in previously treated advanced 
breast cancer (ABC). J Clin Oncol. 2010;28:abstract LBA1011.
  185.  Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of 
rapamycin synergistically enhances chemotherapy-induced cytotoxicity in 
breast cancer cells. Clin Cancer Res. 2004;10:7031–42.
  186.  Mayer IA, Means-Powell J, Shyr Y, Arteaga CL, et al. A phase Ib trial 
of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR 
inhibitor, in patients with metastatic breast cancer. 2009;ASCO Breast 
Cancer Symposium: abstract 254.
  187.  Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-
deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 
2001;98:10314–9.
  188.  Steelman  LS,  Mavolanic  PM,  Sokolosky  ML,  et  al.  Suppression  of 
PTEN function increases breast cancer chemotherapeutic drug resistance 
while  conferring  sensitivity  to  mTOR  inhibitors.  Oncogene.  2008:27: 
4086–95.
  189.  Noh WC, Monesire WH, Peng J, et al. Determinants of rapamycin sensitiv-
ity in breast cancer cells. Clin Can Res. 2004;10:1013–23.
  190.  Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic 
study  of  temserolimus  in  advanced  endocrine  carcinomas.  Br  J  Cancer. 
2006;95:1148–54.
  191.  Atzori F, Tabernero J, Cerbantes A, et al. A phase I, pharmacokinetic 
(PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an 
insulin-like  growth  factor-1  receptor  (IGF1R)  monoclonal  antibody 
(MAb) in patients (pts) with advanced solid tumors. J Clin Oncol. 2008; 
26:3519.
  192.  Higano CS, Yu EY, Whiting MS, et al. A phase I, first in man study of 
weekly  IMC-A12,  a  fully  human  insulin  like  growth  factor-I  receptor 
IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin 
Oncol. 2007;25:abstract 3505.
  193.  Hidalgo M, Tirado Gomez M, Lewis N, et al. A phase I study of MK-0646, 
a humanized monoclonal antibody against the insulin-like growth factor 
receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk 
schedule. J Clin Oncol. 2008;abstract 3520.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Management options in TNBC
Breast Cancer: Basic and Clinical Research 2011:5  199
  194.  Rodon J, Patnaik A, Stein M, et al. A phase I study of q3 W R1507, a 
human monoclonal antibody IGF-1R antagonist in patients with advanced 
cancer. J Clin Oncol. 2007;25:abstract 3590.
  195.  Carlson, RH. IGF-1R biomarker points to new target in triple-negative 
breast cancer. Oncol Times. 2010;32:30–1.
  196.  Traina TA, Wolff AC, Giri D, et al. Androgen receptor inhibition for the 
treatment  of AR/ER-/PR-  metastatic  breast  cancer.  2009;ASCO  Breast 
Cancer Symposium: abstract 251.
  197.  Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy 
with or without bevacizumab: primary efficacy endpoint analysis of the 
geparquinto study (GBG 44). 2011;SABCS:abstract 4–6.